

CITATION REPORT

List of articles citing

Revised response criteria for malignant lymphoma

DOI: 10.1200/jco.2006.09.2403

Journal of Clinical Oncology, 2007, 25, 579-86.

Source: <https://exaly.com/paper-pdf/42325119/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2213	Comparison of whole-body diffusion-weighted magnetic resonance and FDG-PET/CT in the assessment of Hodgkin's lymphoma for staging and treatment response. 2014 , 8, 429		3
2212	PET for follicular lymphoma: a work in progress!. 2007 , 48, 1463-4		5
2211	Clinical features, prognosis and treatment of follicular lymphoma. 2007 , 2007, 216-25		48
2210	The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas. 2007 , 7, 1749-62		7
2209	Peripheral T-cell lymphomas: variably or routinely fluorodeoxyglucose-avid?. 2007 , 48, 1465-7		1
2208	Hodgkin's disease--from pathology specimen to cure. 2007 , 357, 1968-71		35
2207	Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma. 2007 , 48, 1216-8		8
2206	Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat. 2007 , 48, 1667-9		9
2205	Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Szary syndrome. 2007 , 22, 836-40		28
2204	Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. 2007 , 48, 1548-55		45
2203	Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. 2007 , 298, 2289-95		218
2202	FDG-PET in T-cell and NK-cell neoplasms. 2007 , 18, 1685-90		103
2201	18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?. 2007 , 48, 1580-2		41
2200	Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3746-52	2.2	667
2199	Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. 2007 , 48, 1626-32		307
2198	Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1741-6	2.2	221
2197	Is bone marrow biopsy obligatory in all patients with non-Hodgkin's lymphoma?. 2007 , 118, 61-4		8

2196	Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. 2007 , 48, 1767-76	72
2195	How I treat indolent lymphoma. 2007 , 109, 4617-26	78
2194	The role of FDG-PET scans in patients with lymphoma. 2007 , 110, 3507-16	245
2193	Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. 2007 , 29, 667	2
2192	AML1 mutation and FLT3-internal tandem duplication in leukemia transformed from myelodysplastic syndrome. 2007 , 29, 666-7	1
2191	The accuracy of PET(CT) in evaluating pediatric lymphoma. 2007 , 29, 667-8	2
2190	A single unit lymphoma experience: outcome in a Cape Town academic centre. 2007 , 37, 93-102	5
2189	Lymphomas. 2007 , 2, 101-110	1
2188	La TEP-TDM dans la maladie de Hodgkin : expfience clermontoise. 2007 , 31, 562-567	2
2187	FDG-PET scan and treatment planning for early stage Hodgkin lymphoma. 2007 , 85, 176-7	4
2186	Hodgkin lymphoma: Response assessment by revised International Workshop Criteria. 2007 , 48, 1539-47	60
2185	Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. 2007 , 48, 1522-30	35
2184	The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era. 2007 , 48, 2121-36	23
2183	High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma. 2007 , 48, 2444-6	
2182	The International Harmonization Project for response criteria in lymphoma clinical trials. 2007 , 21, 841-54	99
2181	Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?. 2007 , 21, 881-96	3
2180	New strategies for the treatment of advanced-stage Hodgkin's lymphoma. 2007 , 21, 897-914	18
2179	Is [(18)F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?. 2007 , 21, 855-69	8

2178	Relapsed and refractory Hodgkin's lymphoma: new avenues?. 2007 , 21, 929-41	4
2177	Whole body MRI and PET/CT in haematological malignancies. 2007 , 7 Spec No A, S88-93	17
2176	Current Awareness in Hematological Oncology. 2007 , 25, 204-211	
2175	The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. 2007 , 110, 652-9	170
2174	The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. 2007 , 110, 1361-9	64
2173	2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. 2007 , 17, 190-7	41
2172	Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. 2007 , 86, 493-8	114
2171	Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. 2007 , 86, 897-903	86
2170	Is BEACOPP better than ABVD?. 2007 , 2, 161-6	7
2169	CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. 2007 , 38, 19-23	
2168	CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. 2007 , 38, 59-62	4
2167	Breast cancer after treatment of Hodgkin's lymphoma: general review. 2008 , 72, 1291-7	25
2166	Imaging of tumor glucose utilization with positron emission tomography. 2008 , 27, 545-54	62
2165	Highlights of the annual congress of the European Association of Nuclear Medicine, Copenhagen 2007. 2008 , 35, 655-72	1
2164	Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma. 2008 , 35, 1413-20	8
2163	Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. 2008 , 87, 613-21	99
2162	[Differential diagnosis and diagnostic strategies of lymphadenopathy]. 2008 , 49, 305-318; quiz 319-20	9
2161	[Automated procedure for volumetric measurement of metastases: estimation of tumor burden]. 2008 , 48, 857-62	3

2160 FDG-PET scans in patients with lymphoma. **2008**, 3, 197-203

2159 Management of relapsed diffuse large B-cell lymphoma. **2008**, 10, 393-403

7

2158 Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified. **2008**, 25, 360-4

11

2157 Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation. **2008**, 22, 251-60

1

2156 Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma. **2008**, 22, 719-22

20

2155 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence. **2008**, 22, 795-802

13

2154 Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography. **2008**, 88, 149-153

29

2153 The impact of functional imaging on radiation medicine. **2008**, 3, 25

16

2152 Fine-needle aspiration cytology in the follow-up of Hodgkin lymphoma. **2008**, 36, 467-72

5

2151 Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. **2008**, 83, 477-81

16

2150 Bone marrow necrosis complicating post-transplant lymphoproliferative disorder: resolution with rituximab. **2008**, 32, 829-34

5

2149 Subcutaneous alemtuzumab for Szary Syndrome in the very elderly. **2008**, 32, 1299-303

33

2148 Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. **2008**, 71, 180-6

106

2147 Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. **2008**, 71, 213-9

99

2146 Imaging guiding therapy development in lymphoma. **2008**, 84, 443-5

1

2145 Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. **2008**, 42, 529-34

15

2144 Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. **2008**, 99, 253-8

10

2143 Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. **2008**, 41, 39-43

26

2142	Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. 2008 , 99, 1016-20	167
2141	IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosfamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma. 2008 , 141, 244-8	11
2140	Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. 2008 , 142, 52-6	53
2139	Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. 2008 , 142, 786-92	25
2138	Allogeneic transplantation for Hodgkin lymphoma. 2008 , 143, 468-80	17
2137	Aiming at a curative strategy for follicular lymphoma. 2008 , 58, 305-17	31
2136	PET/CT in the management of haematological malignancies. 2008 , 80, 369-80	36
2135	[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. 2008 , 8, 159-65	35
2134	Highlights of the 2008 International Conference on Malignant Lymphoma. 2008 , 8, 205-8	
2133	[18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas. 2008 , 8, 273-6	4
2132	Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?. 2008 , 8, 287-93	58
2131	FDG PET and PET/CT in the Management of Pediatric Lymphoma Patients. 2008 , 3, 621-34	11
2130	[Imaging and PET-CT of adult and childhood lymphoma]. 2008 , 89, 371-84; quiz 385-6	6
2129	FDG-PET Evaluation of Response to Treatment. 2008 , 3, 37-75	3
2128	Staging and evaluation of the patient with lymphoma. 2008 , 22, 825-37, vii-viii	21
2127	Imaging of abdominal lymphoma. 2008 , 46, 265-85, viii-ix	37
2126	Imaging of pediatric lymphomas. 2008 , 46, 313-38, ix	41
2125	Quelques perspectives concernant le traitement des lymphomes par Zevalin® à partir de l'évaluation de l'expérience néo-zélandaise. 2008 , 32, 85-95	

2124	L'avenir de l'oncologie passe-t-il par la médecine nucléaire?. 2008 , 32, 249-253	1
2123	Tomographie à émission de positons et lymphomes. 2008 , 32, 449-455	2
2122	How to assess anti-tumour efficacy by imaging techniques. 2008 , 44, 39-45	35
2121	Response assessment in lymphoma. 2008 , 63, 125-35	22
2120	Indeterminate lesions in cancer imaging. 2008 , 63, 843-52	8
2119	Mantle cell lymphoma: an overview of diagnostic and therapeutic advances. 2008 , 5, 465-472	1
2118	Meeting Highlights. 2008 , 8, 210-218	
2117	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. 2008 , 111, 5446-56	2531
2116	The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. 2008 , 88, 202-10	90
2115	Imaging of lymphoma of the musculoskeletal system. 2008 , 46, 379-96, x	26
2114	Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. 2008 , 9, 766-76	121
2113	New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. 2008 , 46, 213-23, vii	28
2112	The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. 2008 , 46, 199-211, vii	41
2111	Therapy of mantle cell lymphoma: current standards and future strategies. 2008 , 22, 953-63, ix	26
2110	Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. 2008 , 112, 3989-94	170
2109	Non-Hodgkin lymphoma of the Waldeyer's ring: clinicopathologic and therapeutic issues. 2008 , 49, 2263-71	30
2108	PET imaging for response assessment in lymphoma: potential and limitations. 2008 , 46, 225-41, viii	33
2107	Analysis of competing risks of causes of death and their variation over different time periods in Hodgkin's disease. 2008 , 14, 5300-5	10

2106	Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. 2008 , 19, 951-7		1
2105	Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. 2008 , 19, 1331-1335		35
2104	New response criteria for lymphomas in clinical trials. 2008 , 19 Suppl 4, iv35-8		20
2103	Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab. 2008 , 19, 1629-33		12
2102	High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5175-82	2.2	60
2101	Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. 2008 , 19, 964-9		144
2100	18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. 2008 , 49, 13-21		125
2099	Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2717-24	2.2	228
2098	Tumor cell metabolism imaging. 2008 , 49 Suppl 2, 43S-63S		236
2097	Primary mediastinal B-cell lymphoma. 2008 , 349-58		57
2096	Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. 2008 , 49, 1745-51		84
2095	Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. 2008 , 14, 7088-94		79
2094	Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. 2008 , 19, 1770-3		91
2093	Positron emission tomography and CT in the management of lymphoma. 2008 , 20, 169-175		1
2092	Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2008 , 19 Suppl 2, ii65-6		11
2091	FDG-PET staging of head and neck cancer--can improved imaging lead to improved treatment?. 2008 , 100, 688-9		9
2090	Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2008 , 19 Suppl 2, ii77-8		5
2089	18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?. 2008 , 49, 9-12		26

2088	Relationship between the response to treatment and the prognosis of patients with aggressive lymphomas treated with chemotherapy followed by involved-field radiotherapy: radiographic assessment. 2008 , 38, 43-8	1
2087	Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2008 , 19 Suppl 2, ii67-9	13
2086	Early interim PET scan in Hodgkin lymphoma: where do we stand?. 2008 , 49, 659-62	31
2085	Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: a single centre experience. 2008 , 49, 1321-8	19
2084	Positron emission tomography in mantle cell lymphoma. 2008 , 49, 1693-701	47
2083	Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review. 2008 , 49, 1762-8	7
2082	What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?. 2008 , 49, 1653-6	5
2081	The mysteries of mantle cell lymphoma--do PET scans provide a clue?. 2008 , 49, 1662-3	2
2080	Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database. 2008 , 49, 1311-20	33
2079	Therapiemonitoring mit 18F-FDG-PET / CT. 2008 , 31, 25-28	1
2078	Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning. 2008 , 5, 160-70	97
2077	Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis. 2008 , 5, 234-8	7
2076	B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience. 2008 , 246, 895-902	27
2075	Synchronous presentation of systemic and brain non-Hodgkin lymphoma. 2008 , 49, 2370-3	3
2074	Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. 2008 , 93, 390-7	38
2073	Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. 2008 , 93, 1364-71	58
2072	[Diagnosis and treatment of malignant lymphoma: discussion]. 2008 , 97, 1637-54	
2071	Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity. 2008 ,	

2070	FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. 2008 , 20, 206-19		55
2069	Bibliography. Current world literature. Lung and mediastinum. 2008 , 20, 234-5		1
2068	PET scanning and prognosis in Hodgkin's lymphoma. 2008 , 20, 509-16		8
2067	Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. 2008 , 85, 707-12		69
2066	Predictive and prognostic value of FDG-PET. 2008 , 8, 70-80		40
2065	Role of PET/CT scanning in initial and post-treatment assessment of Hodgkin disease. 2008 , 6, 623-32		4
2064	The prognostic value of PET and PET/CT in cervical cancer. 2008 , 8, 146-55		47
2063	Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. 2009 , 2, 229-42		4
2062	[Therapy of mantle cell lymphoma]. 2009 , 150, 2253-7		
2061	Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. 2009 , 10, 104-9		43
2060	La place de la TEP au FDG dans l'évaluation des lymphomes. 2009 , 15, 305-312		
2059	Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1781-7	2.2	143
2058	Rituximab and chemotherapy in primary gastric lymphoma. 2009 , 24, 25-8		25
2057	A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. 2009 , 114, 2051-9		147
2056	A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. 2009 , 15, 7701-7710		35
2055	Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. 2009 , 20, 503-7		69
2054	Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. <i>Journal of Clinical Oncology</i> , 2009 , 27, 453-9	2.2	406
2053	18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. 2009 , 50, 8-17		56

2052 Lymphomatous meningitis diagnosed with [18F]-fluorodeoxyglucose-positron-emission tomography/CT. **2009**, 30, E150-1

2051 The case against heavy PETing. *Journal of Clinical Oncology*, **2009**, 27, 1742-3 2.2 40

2050 p63 protein expression in high risk diffuse large B-cell lymphoma. **2009**, 62, 77-9 23

2049 PET imaging in lymphoma. **2009**, 2, 261-76 3

2048 Follicular lymphoma: the case for timely intervention. **2009**, 2, 277-84

2047 Standards for PET image acquisition and quantitative data analysis. **2009**, 50 Suppl 1, 11S-20S 592

2046 Improving cancer outcomes through international collaboration in academic cancer treatment trials. *Journal of Clinical Oncology*, **2009**, 27, 5109-14 2.2 42

2045 Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. **2009**, 20 Suppl 4, 119-20 15

2044 Measuring response with FDG-PET: methodological aspects. **2009**, 14, 369-77 57

2043 Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. **2009**, 20, 1086-93 96

2042 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. **2009**, 50, 88-99 242

2041 Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. *Journal of Clinical Oncology*, **2009**, 27, 426-32 2.2 136

2040 CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. **2009**, 192, 745-53 64

2039 Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?. **2009**, 50, 1931-6 28

2038 Rituximab in lymphocyte-predominant Hodgkin disease. **2009**, 76, 26-9 11

2037 Mantle cell lymphoma in the orbital and adnexal region. **2009**, 93, 1047-51 48

2036 Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. **2009**, 50, 1760-9 59

2035 The recent decline in mortality from Hodgkin lymphomas in central and eastern Europe. **2009**, 20, 767-74 20

2034	Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. 2009 , 94, 550-65		59
2033	Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. 2009 , 20, 709-14		69
2032	FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. 2009 , 20, 1270-4		43
2031	Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. 2009 , 20, 1985-92		60
2030	Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2009 , 20 Suppl 4, 110-2		30
2029	Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. 2009 , 15, 3503-10		49
2028	Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. 2009 , 101, 248-55		136
2027	Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. 2009 , 14 Suppl 2, 30-40		46
2026	Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. 2009 , 114, 2945-51		141
2025	New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary. 2009 , 14 Suppl 2, 52-4		
2024	PET/CT for therapy response assessment in lymphoma. 2009 , 50 Suppl 1, 21S-30S		158
2023	Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4555-62	2.2	483
2022	Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. 2009 , 34, 1408-16		117
2021	Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. 2009 , 82, 184-93		18
2020	Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. 2010 , 85, 81-3		17
2019	Endogenous thrombin potential in the assessment of hypercoagulability in systemic lupus erythematosus. 2010 , 85, 83-5		5
2018	HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma: report of two cases. 2010 , 85, 85-7		20
2017	The number of people with sickle-cell disease in the United States: national and state estimates. 2010 , 85, 77-8		193

2016	Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. 2010 , 85, 87-90	19
2015	Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacement. 2010 , 85, 79-81	7
2014	Involved field radiotherapy for limited stage Hodgkin lymphoma: balancing treatment efficacy against long-term toxicities. 2009 , 27, 115-22	4
2013	Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation. 2009 , 115, 4980-9	20
2012	Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values. 2009 , 14, 150-8	4
2011	Szintigraphie und Single-Photon-Emissions-Computertomographie (SPECT und PET). 2009 , 15, 474-486	
2010	NEC density and liver ROI S/N ratio for image quality control of whole-body FDG-PET scans: comparison with visual assessment. 2009 , 11, 480-6	16
2009	What is the best treatment for children with limited-stage Hodgkin lymphoma?. 2009 , 4, 129-35	8
2008	Prognostic factors in low-grade non-Hodgkin lymphomas. 2009 , 4, 202-10	11
2007	Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. 2009 , 36, 745-50	59
2006	Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?. 2009 , 88, 1107-12	3
2005	Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma. 2009 , 88, 1229-36	36
2004	Primary Nasopharyngeal non-Hodgkin lymphomas: a retrospective review of 26 Moroccan patients. 2009 , 9, 11	10
2003	High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. 2009 , 144, 524-30	57
2002	Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. 2009 , 145, 369-72	46
2001	Abstracts of the XXII International Symposium on Technological Innovations in Laboratory Hematology. May, 11-14, 2009. Las Vegas, Nevada, USA. 2009 , 31 Suppl 1, 1-111	
2000	Bcl-xL gene expression correlated with lower apoptotic cell numbers and shorter progression-free survival in PCFCL. 2009 , 129, 1703-9	11
1999	Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. 2009 , 23, 777-83	185

1998	Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. 2009 , 43, 37-42		13
1997	Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. 2009 , 43, 327-33		14
1996	Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT. 2009 , 43, 323-5		6
1995	The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. 2009 , 43, 941-8		43
1994	Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs. 2009 , 44, 19-25		4
1993	Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma. 2009 , 44, 287-93		5
1992	Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. 2009 , 9, 675-81		85
1991	Clinicopathological comparison of the World Health Organization/Wotherspoon score to the Groupe d'Etude des Lymphomes de l'Adult grade for the post-treatment evaluation of gastric mucosa-associated lymphoid tissue lymphoma. 2009 , 24, 307-15		9
1990	Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. 2009 , 49, 1890-900		31
1989	Positron Emission Tomography in oncology: present and future of PET and PET/CT. 2009 , 72, 239-54		37
1988	Molecular imaging with bioconjugates in mouse models of cancer. 2009 , 20, 631-43		26
1987	L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. 2009 , 20, 110-6		90
1986	Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1456-61	2.2	45
1985	Assessing tumor response to therapy. 2009 , 50 Suppl 1, 1S-10S		193
1984	New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 2009 , 45, 228-47		16132
1983	Evaluation of lymph nodes with RECIST 1.1. 2009 , 45, 261-7		184
1982	Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. 2009 , 15, 1447-54		33
1981	Medical management update: Non-Hodgkin lymphoma. 2009 , 107, e19-33		34

1980	Le radiopharmaceutique : situation et perspectives depuis la 8e Confrence internationale de lâACOMEN (Bordeaux, 11â2â3 mai 2005). 2009 , 33, 115-121	2
1979	Apport de la tomographie âmission de positons au 18F-fluorodâxyglucose dans la prise en charge des lymphomes folliculaires. 2009 , 33, 363-374	1
1978	Injection de produit de contraste ? Arguments dân mâecin nuclâire en faveur des injections. 2009 , 33, 290-293	
1977	Les essais cliniques en mâecine nuclâire : âtat et perspectives. 2009 , 33, 296-304	
1976	La place de la TEP au FDG dans lâvaluation des lymphomes. 2009 , 33, 486-490	4
1975	From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. 2009 , 50 Suppl 1, 122S-50S	2458
1974	94 Patient-reported outcomes in cancer research. 2009 , 7, 24-25	
1973	95 New PET-Tracers for imaging pathophysiology and response. 2009 , 7, 25	
1972	96 PET imaging of non-Hodgkin lymphoma: defining methodologies for early prediction of response. 2009 , 7, 25	
1971	18F-fluorodeoxyglucose positron emission tomography in the evaluation of therapy response assessment in lymphomas. Systematic literature review and meta-analysis. 2009 , 28, 48-55	
1970	Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?. 2009 , 50, 1992-8	8
1969	Rituximab and dose-dense chemotherapy in primary testicular lymphoma. 2009 , 9, 386-9	19
1968	Rituximab as maintenance therapy for patients with follicular lymphoma. 2009 , CD006552	17
1967	Non-Hodgkin lymphoma response evaluation with MRI texture classification. 2009 , 28, 87	33
1966	High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. 2009 , 20, 309-18	122
1965	Clinicopathologic features and treatment outcome of non-Hodgkin lymphoma of the breast--a review of 42 primary and secondary cases in Taiwanese patients. 2009 , 50, 918-24	24
1964	Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes. 2009 , 50, 1750-2	6
1963	Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. 2009 , 50, 1824-9	4

1962	Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial. 2009 , 50, 1757-60	39
1961	MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. 2009 , 62, 715-23	18
1960	Monitoring response to therapeutic interventions in patients with cancer. 2009 , 39, 210-32	31
1959	Presentation and management of intravascular large B-cell lymphoma. 2009 , 10, 895-902	210
1958	Tomografía de positrones con 18F-fluorodesoxiglucosa en la valoración de la respuesta de los linfomas al tratamiento. Revisión sistemática de la literatura y metaanálisis. 2009 , 28, 48-55	4
1957	Standardised tumour, node and metastasis reporting of oncology CT scans. 2009 , 53, 345-52	3
1956	Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). 2009 , 16, 181-6	17
1955	Utility of positron emission tomography in the mediastinum: moving beyond lung and esophageal cancer staging. 2009 , 19, 7-15	13
1954	L'Évaluation en oncologie : comment je fais en imagerie ?. 2009 , 49, 392-406	
1953	Localized large cell lymphoma: is there any need for radiation therapy?. 2009 , 21, 401-6	16
1952	Splenic follicular lymphoma: clinicopathologic characteristics of a series of 32 cases. 2009 , 33, 730-8	35
1951	Salvage therapy for Hodgkin's lymphoma. 2009 , 15, 161-3	31
1950	Better infrastructure for critical care trials: nomenclature, etymology, and informatics. 2009 , 37, S173-7	8
1949	The utility of FDG-PET for managing patients with malignant lymphoma: analysis of data from a single cancer center. 2009 , 48, 1509-13	6
1948	Évaluation par imagerie en cancérologie : de la définition des standards internationaux à l'exercice pratique. 2009 , 4, 1-12	
1947	TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. 2009 , 114, 1099-109	133
1946	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. 2009 , 113, 18-27	91
1945	Tumors of the Pharynx, Tongue, and Mouth. 2009 , 589-618	

1944	Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?. 2009 , 15, 354-60	13
1943	Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective. 2009 , 15, 957-65	11
1942	Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. 2009 , 33, 591-8	26
1941	Lymphomes des voies aodigestives suprieures. 2010 , 5, 1-8	2
1940	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 2010 , 95, 1792-6	74
1939	False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt's lymphoma. 2010 , 31, 232-8	34
1938	Interesting image. Unsuspected synchronous thyroid carcinoma revealed on a post-therapy F-18 FDG PET/CT, in a patient with follicular lymphoma. 2010 , 35, 879-81	8
1937	Role of early PET in the management of diffuse large B-cell lymphoma. 2010 , 22, 414-8	17
1936	Anthracyclines-containing regimens for treatment of follicular lymphoma in adults. 2010 ,	1
1935	9. Current Treatment and Future Prospects of Malignant Lymphoma.. 2010 , 99, 542-547	
1934	NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. 2010 , 8, 288-334	185
1933	A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma. 2010 , 95, 1198-206	23
1932	Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. 2010 , 95, 1046-8	25
1931	18F-FDG PET/CT evaluation of lymphoma with renal involvement: comparison with renal carcinoma. 2010 , 103, 642-9	25
1930	[Not Available]. 2010 , 65, 367-72	1
1929	Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need. 2010 , 65, 373-7, 367-72	2
1928	PET positive, PET negative, or PET peeve?. 2010 , 115, 752-3	4
1927	Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. 2010 , 116, 1795-802	60

1926	Rosai-Dorfman disease: FDG PET/CT findings in a patient presenting with pyrexia and cervical adenopathy. 2010 , 35, 576-8		10
1925	An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. 2010 , 8, 347-52		21
1924	Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. 2010 , 95, 1350-7		34
1923	RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. 2010 , 20, 1456-67		124
1922	Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. 2010 , 20, 2027-38		134
1921	In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4324-32	2.2	376
1920	Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. 2010 , 37, 494-504		68
1919	(18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. 2010 , 37, 1095-105		111
1918	Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. 2010 , 37, 1633-42		66
1917	Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. 2010 , 37, 2307-14		101
1916	18F-FDG PET/CT in primary non-Hodgkin's lymphoma of the sinonasal tract. 2010 , 89, 635-7		5
1915	A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. 2010 , 89, 1107-13		26
1914	[Molecular imaging in cancer therapy]. 2010 , 53, 810-7		
1913	Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. 2010 , 136, 883-9		73
1912	PET beim Hodgkin-Lymphom. 2010 , 16, 18-27		1
1911	Qualitative and quantitative assessment of endpoints in clinical trials. 2010 , 3, 33-36		0
1910	SEOM clinical guidelines for the treatment of Hodgkin's lymphoma. 2010 , 12, 753-9		1
1909	F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma. 2010 , 24, 115-9		2

1908	Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience. 2010 , 91, 78-86	13
1907	Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?. 2010 , 92, 246-54	29
1906	Incidental carcinomas detected by PET/CT scans in patients with malignant lymphoma. 2010 , 92, 647-50	14
1905	Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. 2010 , 92, 732-43	33
1904	CHOP-like regimen in combination with rituximab and peginterferon alpha-2b in newly-diagnosed diffuse large B-cell Non-Hodgkin's lymphoma: Experience in a Chinese center. 2010 , 7, 103-109	
1903	Clinical analysis of 13 cases with Burkitt lymphoma or Burkitt-like lymphoma. 2010 , 7, 110-115	
1902	On the added value of baseline FDG-PET in malignant lymphoma. 2010 , 12, 225-32	27
1901	[CT-PET and evaluation of therapy response. is the size really important?]. 2010 , 29, 184-8	3
1900	Improving outcomes for patients with diffuse large B-cell lymphoma. 2010 , 60, 393-408	100
1899	If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. 2010 , 10, 644	20
1898	Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. 2010 , 85, 149-57	28
1897	Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 2010 , 85, 405-15	25
1896	PET/CT in cancer research: from preclinical to clinical applications. 2010 , 5, 190-200	12
1895	Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. 2010 , 116, 3835-42	64
1894	Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 2010 , 116, 5667-75	13
1893	Multicentre phase II study of CycLOBEAP plus rituximab in patients with diffuse large B-cell lymphoma. 2010 , 28, 68-74	9
1892	Endothelial cells (EC) and endothelial precursor cells (EPC) kinetics in hematological patients undergoing chemotherapy or autologous stem cell transplantation (ASCT). 2010 , 28, 192-201	5
1891	Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology. 2010 , 85, 147-55	5

1890	Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. 2010 , 85, 894-6	149
1889	Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. 2010 , 85, 896-9	87
1888	Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. 2010 , 85, 904-7	2
1887	Comparison of real-time microvascular abnormalities in pediatric and adult sickle cell anemia patients. 2010 , 85, 899-901	26
1886	Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis. 2010 , 85, 902-4	13
1885	2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. 2010 , 34, 184-9	26
1884	Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. 2010 , 34, 454-7	11
1883	Synthesis and in vitro evaluation of 18F labeled tyrosine derivatives as potential positron emission tomography (PET) imaging agents. 2010 , 20, 3482-5	6
1882	Diagnosis and staging in gastrointestinal lymphoma. 2010 , 24, 3-12	26
1881	Quantification of local tumor response to fractionated radiation therapy for non-Hodgkin lymphoma using weekly 18F-FDG PET/CT imaging. 2010 , 76, 850-8	5
1880	Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review. 2010 , 76, 1166-70	2
1879	Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma. 2010 , 78, 507-12	17
1878	Standard- versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization. 2010 , 50, 2432-46	11
1877	Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document. 2010 , 8, 28-37	178
1876	Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. 2010 , 101, 2059-64	47
1875	Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. 2010 , 148, 810-2	10
1874	High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. 2010 , 148, 890-7	70
1873	Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. 2010 , 149, 455-7	30

1872	Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. 2010 , 150, 39-45			62
1871	Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. 2010 , 151, 221-31			45
1870	Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. 2010 , 24, 1343-9			46
1869	Quantitation of whole blood Epstein-Barr virus DNA is useful for assessing treatment response in patients with non-Hodgkin's lymphoma. 2010 , 32, e106-13			8
1868	Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma. 2010 , 14, 109-14			2
1867	Radioimmunotherapy for B-Cell Non-Hodgkin Lymphoma. 2010 , 169-218			
1866	. 2010 ,			15
1865	The Role of Molecular Imaging in Evaluating Tumor Response to Targeted Radiotherapy. 2010 , 527-542			
1864	Lymphome de Hodgkin de l'adulte. 2010 , 16, 39-44			
1863	Tumour response evaluation with fluorodeoxyglucose positron emission tomography: research technique or clinical tool?. 2010 , 10 Spec no A, S68-72			8
1862	Whole-body diffusion-weighted imaging in lymphoma. 2010 , 10 Spec no A, S172-8			33
1861	COMPROMISO MUSCULAR POR LINFOMA NO HODGKIN: CASO CLÍNICO Y REVISIÓN DEL TEMA. 2010 , 16,			1
1860	T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3695-700	2.2		124
1859	Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation. 2010 , 21, 1211-1216			13
1858	Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. 2010 , 16, 1894-903			131
1857	(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. 2010 , 51, 25-30			292
1856	Reply to A. Hittmann et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e490-e491	2.2		1
1855	Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1896-903	2.2		254

1854	How I treat elderly patients with diffuse large B-cell lymphoma. 2010 , 116, 5103-10	108
1853	FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. 2010 , 30, 269-91	214
1852	Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 2010 , 115, 2578-85	612
1851	FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. 2010 , 21, 1877-1883	25
1850	Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 2010 , 16, 3998-4004	51
1849	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v168-71	35
1848	CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. 2010 , 2, 41ra52	72
1847	Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. 2010 , 70, 9062-72	114
1846	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v181-3	22
1845	18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. 2010 , 51, 1337-43	115
1844	Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. 2010 , 254, 245-52	26
1843	Unresolved issues in diffuse large B-cell lymphomas. 2010 , 10, 387-402	4
1842	Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. 2010 , 21, 1078-82	84
1841	Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v172-4	52
1840	131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. 2010 , 51, 1155-62	68
1839	Improved prognosis for localized malignant lymphomas of the head and neck. 2010 , 130, 626-31	3
1838	Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. 2010 , 15, 750-9	41
1837	Exploring the role of FDG-PET in the assessment of bone marrow involvement in lymphoma patients as interpreted by qualitative and semiquantitative disease metabolic activity parameter. 2010 , 47, 380-4	4

1836	Measurement accuracy and reproducibility of semiautomated metric and volumetric lymph node analysis in MDCT. 2010 , 195, 979-85	19
1835	The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. 2010 , 51 Suppl 1, 28-33	21
1834	Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. 2010 , 51, 2063-9	13
1833	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. 2010 , 95, 1342-9	106
1832	Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. 2010 , 21, 1217-1221	17
1831	(18)F-deoxyglucose PET: useful in the management of patients with stem cell transplantation for lymphoma?. 2010 , 3, 405-10	5
1830	Hodgkin lymphoma in HIV positive patients. 2010 , 8, 141-6	11
1829	Clinical utility of PET/CT in lymphoma. 2010 , 194, W91-W103	95
1828	Linfomi delle vie aerodigestive superiori. 2010 , 9, 1-8	
1827	Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. 2010 , 70, 1445-76	144
1826	Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?. 2010 , 10, 270-7	28
1825	A decade of progress in lymphoma: advances and continuing challenges. 2010 , 10, 414-23	38
1824	15 Mantle cell lymphoma: Current standards and new approaches. 2010 , 8, 9-10	
1823	16 Autologous transplantation in lymphoma: Has rituximab changed the scenario?. 2010 , 8, 10	
1822	17 Fluorodeoxyglucose (FDG) positron emission tomography (PET) in Lymphoma. 2010 , 8, 10	
1821	Handbook of Evidence-Based Radiation Oncology. 2010 ,	32
1820	The indolent course and high incidence of t(14;18) in primary duodenal follicular lymphoma. 2010 , 21, 1500-1505	27
1819	Early [¹⁸ F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report. 2010 , 27, 650-7	2

1818	Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. 2010 , 21, 2246-2254	51
1817	The Bone Marrow in Normal and Disease States. 2010 , 99-121	1
1816	Therapy of B-cell Lymphoproliferative Disorders. 2010 , 323-332	1
1815	Treatment of Hodgkin Lymphoma. 2010 , 367-389	
1814	High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment. 2010 , 51, 1260-8	13
1813	Point de vue d'un mēdecin nuclāire pratiquant les examens hybrides avec injection de produit de contraste. 2010 , 34, 439-443	1
1812	Intřt de la TEP au 18F-FDG prřthřapeutique pour prřdire la rřponse ř la radio-immunothřrapie dans les lymphomes non hodgkiniens. 2010 , 34, 647-654	
1811	Apport de la TEP/TDM au 18FDG dans la stadification initiale et l'řvaluation prřcoce de la rřponse thřrapie des rhabdomyosarcomes pđiatriques. 2010 , 34, 655-663	2
1810	Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma. 2010 , 64, 83-7	4
1809	Follicular non-Hodgkin's lymphoma. 2010 , 65, 408-20	12
1808	Two decades at the cross-roads of biology, physics and epidemiology: lessons learned in [18F]-FDG positron emission tomography in oncology. 2010 , 46, 2150-8	1
1807	PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. 2010 , 73, 470-80	52
1806	New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma. 2010 , 16, 376-83	22
1805	Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. 2010 , 16, 1145-54	18
1804	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: acute leukemias and myelodysplastic syndromes. 2010 , 16, 1187-211	66
1803	NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. 2010 , 16, 1325-46	29
1802	Lymphoma--emerging realities in sub-Saharan Africa. 2010 , 42, 141-50	12
1801	[Handling the therapeutic response from the tumor with PET]. 2010 , 29, 273-4	3

1800 Linfomas de las vías aerodigestivas superiores. **2010**, 39, 1-9

1799 Developments in the management of Hodgkin's lymphoma. **2010**, 375, 786-8

9

1798 Therapy response evaluation with positron emission tomography-computed tomography. **2010**, 31, 490-5

3

1797 Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. *Journal of Clinical Oncology*, **2010**, 28, 4485-91

2.2

502

1796 Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. **2010**, 363, 1812-21

1079

1795 Imaging of lymphoma of the musculoskeletal system. **2010**, 18, 75-93

5

1794 Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. **2010**, 17, 1175-85

5

1793 Clinicopathologic features and treatment options of ocular adnexal lymphoma. **2010**, 5, 241-258

1792 Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases. **2010**, 49, 526-8

1791 Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. **2010**, 51, 1225-32

31

1790 Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. **2010**, 51, 2208-14

10

1789 Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia. **2010**, 51, 1767-70

1

1788 FDG PET/CT versus CT, MR imaging, and ⁶⁷Ga scintigraphy in the posttherapy evaluation of malignant lymphoma. **2010**, 30, 939-57

36

1787 Patterns of survival of follicular lymphomas at a single institution through three decades. **2010**, 51, 1028-34

29

1786 Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. **2010**, 116, 5119-25

107

1785 Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. **2010**, 21, 1222-1227

36

1784 A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. **2010**, 49, 3-12

27

1783 SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. **2010**, 51, 279-83

50

1782	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. 2011 , 52, 823-32		20
1781	Economic impact of disease progression in follicular non-Hodgkin lymphoma. 2011 , 52, 2117-23		13
1780	Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 2011 , 52, 1585-8		43
1779	Highlights in lymphoma: overview of the 11th International Conference on Malignant Lymphoma. 2011 , 4, 491-4		3
1778	An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant. 2011 , 52, 1249-54		5
1777	Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy. 2011 , 52, 1689-96		4
1776	Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. 2011 , 52, 1255-61		38
1775	First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2766-72	2.2	135
1774	Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. 2011 , 52, 1488-94		32
1773	BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. 2011 , 118, 3419-25		94
1772	Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. 2011 , 52, 786-95		1
1771	Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study. 2011 , 38, 2198-208		66
1770	Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3389-95	2.2	91
1769	Role of functional imaging in the management of lymphoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1844-54		211
1768	Leukemia and lymphoma. 2011 , 49, 767-97, vii		27
1767	A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment. 2011 , 6, 299-311		3
1766	Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 2011 , 11, 462-6		92
1765	Treatment of indolent lymphoma in Germany - results of a representative population-based survey. 2011 , 11, 204-11		8

1764	FDG-PET/CT in lymphoma. 2011 , 727, 1-19	34
1763	Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. 2011 , CD007110	28
1762	Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. 2011 , CD007941	26
1761	Opportunities and pitfalls of cancer imaging in clinical trials. 2011 , 8, 517-27	28
1760	[Non-Hodgkin's lymphoma staging: a prospective study of the value of positron emission tomography/computed tomography (PET/CT) versus PET and CT]. 2011 , 137, 383-9	6
1759	Romidepsin: in the treatment of T-cell lymphoma. 2011 , 71, 1469-80	18
1758	Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials. 2011 , 11, 23-32	10
1757	Target Definitions for Hodgkin Lymphoma: The Involved Node Radiation Field Concept. 2011 , 91-122	
1756	The Role of Imaging in Radiotherapy for Hodgkin Lymphoma. 2011 , 81-89	1
1755	Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. 2011 , 118, 4053-61	123
1754	Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. 2011 , 52, 387-93	31
1753	Hodgkin Lymphoma. 2011 ,	3
1752	Radiotherapy for Hodgkin Lymphoma. 2011 ,	2
1751	Oncogfiatrie. 2011 ,	
1750	Imaging in follicular NHL. 2011 , 24, 165-77	14
1749	Perspective of clinical research in follicular NHL: interaction between science and industry. 2011 , 24, 313-21	1
1748	Prognostic significance of interim 18 F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. 2011 , 47, 1312-8	69
1747	No correlation between glucose metabolism and apparent diffusion coefficient in diffuse large B-cell lymphoma: a PET/CT and DW-MRI study. 2011 , 79, e117-21	33

1746	Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning. 2011 , 17, 867-74		28
1745	Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome. 2011 , 17, 1497-504		37
1744	Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. 2011 , 17, 1646-52		76
1743	Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. 2011 , 52 Suppl 3, 1-14		15
1742	Anaplastic lymphoma kinase expression in a recurrent primary cutaneous anaplastic large cell lymphoma with eventual systemic involvement. 2011 , 65, 671-673		7
1741	Évaluation de la réponse au traitement du lymphome avec la TEP 18F-FDG : existe-t-il un consensus dans l'évaluation de la réponse ? 2011 , 35, 29-37		1
1740	Évaluation de la réponse au traitement des lymphomes : rôle de la TEP-FDG. 2011 , 35, 21-28		
1739	TEP/TDM au FDG et bilan initial des lymphomes : du diagnostic au pronostic. 2011 , 35, 8-20		2
1738	Évaluation de la réponse thérapeutique par tomographie par émission de positons (TEP) au 18fluoro-désoxyglucose (FDG) en oncologie-hématologie. 2011 , 35, 600-607		5
1737	PET/CT scanning with a high HIV/AIDS prevalence. 2011 , 44, 167-72		15
1736	Optimising the lymphoma response criteria in the era of targeted therapy. 2011 , 12, 616-7		10
1735	Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. 2011 , 12, 1222-8		141
1734	Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 971-8	2.2	98
1733	Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance. 2011 , 48, 172-84		39
1732	Volume and attenuation computed tomography measurements for interim evaluation of Hodgkin and follicular lymphoma as an additional surrogate parameter for more confident response monitoring: a pilot study. 2011 , 11, 155-62		1
1731	Radiation Therapy for Hodgkin Lymphoma and Other Hematopoietic Disorders. 2011 , 1099-1140		
1730	Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin's lymphoma using 18F-FDG-PET/CT. 2011 , 58, 291-7		3
1729	Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma. 2011 , 46, 180-5		2

1728	Primary gastrointestinal lymphoma. 2011 , 17, 697-707		237
1727	Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma. 2011 , 46, 103-10		12
1726	Neck Lymphoma. 2011 , 341-361		
1725	Clinical trial risk in Non-Hodgkin's lymphoma: endpoint and target selection. 2011 , 14, 227-35		14
1724	Hodgkin Lymphoma. 2011 , 599-623		1
1723	Retrospective web-based multicenter evaluation of ^{68}Ga -FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphoma. 2011 , 50, 39-47		7
1722	Bendamustine for patients with B cell lymphoid malignancies. 2011 ,		0
1721	Current and future trends in imaging informatics for oncology. 2011 , 17, 203-10		11
1720	Is there a role for bortezomib combinations in the management of patients with follicular lymphoma?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3349-50	2.2	6
1719	Role of rituximab for first-line or relapsed aggressive B-cell lymphoma. 2011 ,		1
1718	Lymphome de Hodgkin de l'adulte. 2011 , 6, 1-17		1
1717	Lymphomes non hodgkiniens': prise en charge. 2011 , 6, 1-6		1
1716	Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. 2011 , 117, 1817-21		32
1715	Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. 2011 , 117, 1834-9		278
1714	How I treat: diagnosing and managing "in situ" lymphoma. 2011 , 117, 3954-60		53
1713	Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. 2011 , 117, 5314-20		52
1712	High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. 2011 , 117, 6977-86		112
1711	miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. 2011 , 118, 1034-40		73

1710	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. 2011 , 118, 5517-27	63
1709	Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. 2011 , 118, 5989-95	357
1708	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. 2011 , 118, 4421-30	28
1707	PET-CT in MM: a new definition of CR. 2011 , 118, 5984-5	10
1706	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. 2011 , 96, 1136-43	74
1705	Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. 2011 , 6, e16408	77
1704	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. 2011 , 96, 996-1001	75
1703	Primary gastric diffuse large B-cell lymphoma with orbital involvement: diagnostic usefulness of 18F-fluorodeoxyglucose positron emission tomography. 2011 , 50, 1953-6	4
1702	[Lymphoid malignancies: progress in diagnosis and treatment. Topics: II. Basic knowledge of lymphoid malignancies; 2. Imaging studies in lymphoma]. 2011 , 100, 1794-800	1
1701	Non-Hodgkin's lymphomas. 2011 , 9, 484-560	47
1700	Hodgkin lymphoma. 2011 , 9, 1020-58	35
1699	Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study. 2011 , 46, 341-9	64
1698	Malignant lymphoma of the lacrimal gland: a nation-based study. 2011 , 129, 1275-80	41
1697	Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study. 2011 , 102, 414-8	8
1696	Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. 2011 , 102, 1687-92	23
1695	Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. 2011 , 152, 175-81	23
1694	Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. 2011 , 152, 551-60	115
1693	Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. 2011 , 153, 191-8	18

1692	Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. 2011 , 153, 334-40	16
1691	Multicentre phase II study of the CycLOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers. 2011 , 153, 582-8	9
1690	Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy. 2011 , 154, 579-89	42
1689	Chemotherapy only for localized Hodgkin lymphoma. 2011 , 270, 197-205	7
1688	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. 2011 , 104, 719-25	36
1687	The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. 2011 , 25, 1502-9	138
1686	Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas. 2011 , 87, 547-53	2
1685	Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome. 2011 , 41, 415-23	103
1684	Personalized treatment of lymphoma: promise and reality. 2011 , 38, 225-35	8
1683	Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia. 2011 , 27, 1987-93	8
1682	Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. 2011 , 29, 154-60	8
1681	Early treatment response evaluation in patients with diffuse large B-cell lymphoma--a pilot study comparing volumetric MRI and PET/CT. 2011 , 13, 785-92	16
1680	Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals. 2011 , 123, 269-75	
1679	Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast. 2011 , 284, 405-9	8
1678	Molekulare Bildgebung in der Tumorthherapie. 2011 , 17, 395-404	
1677	Traitement de maintenance des lymphomes malins non hodgkiniens. 2011 , 13, 543-547	
1676	Place de la tomographie par mission de positons au F18-fluorodéoxyglucose couplé au scanner (TEP/TDM) dans le bilan initial des lymphomes de l'adulte. 2011 , 13, 571-575	
1675	ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study. 2011 , 24, 1-8	29

1674	Molecular imaging in cancer treatment. 2011 , 38, 358-77	64
1673	Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. 2011 , 38, 832-42	47
1672	Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. 2011 , 38, 1064-71	73
1671	Manifestation of lymphoma expansion following lymphatic drainage on 18F-FDG PET/CT. 2011 , 38, 2100-1	1
1670	Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. 2011 , 38, 1620-7	10
1669	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). 2011 , 90, 401-8	21
1668	Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. 2011 , 90, 557-68	30
1667	Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma. 2011 , 90, 693-9	7
1666	Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. 2011 , 90, 797-802	66
1665	Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results. 2011 , 90, 1399-407	12
1664	Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. 2011 , 90, 1409-18	4
1663	Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. 2011 , 68, 165-75	7
1662	t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. 2011 , 68, 1387-95	11
1661	Clinical characterization and prognostic factors of primary lymphoma of bone in case of Chinese patients. 2011 , 28 Suppl 1, S476-82	5
1660	Pediatric Hodgkin Lymphoma: CT features at presentation, on treatment and its prognostic significance. 2011 , 78, 549-54	2
1659	Is contrast material needed after treatment of malignant lymphoma in positron emission tomography/computed tomography?. 2011 , 25, 93-9	9
1658	Impact of FDG-PET/CT in the management of lymphoma. 2011 , 25, 701-16	33
1657	High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. 2011 , 93, 502-508	63

1656	The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. 2011 , 27, 136-45	1
1655	Value of FDG-PET/CT using unfractionated heparin for managing primary cardiac lymphoma and several key findings. 2011 , 18, 516-20	21
1654	Advances in primary CNS lymphoma: randomized clinical trials of chemotherapy and whole-brain radiotherapy. 2011 , 11, 243-5	2
1653	MRI for staging lymphoma: whole-body or less?. 2011 , 33, 1144-50	5
1652	Feasibility of the TNM-based staging system of ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). 2011 , 86, 262-6	37
1651	New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia. 2011 , 86, 619-21	3
1650	The impact of osteoporosis (as measured by lumbar spine quantitative computed tomography) on disease activity and survival in myeloma patients: a 13-year prospective study. 2011 , 86, 617-9	5
1649	Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern province have similar HBB haplotypes but higher HbF levels than African Americans. 2011 , 86, 612-4	26
1648	Hematological characteristics and effective screening for compound heterozygosity for Hb constant spring and deletional β -thalassemia. 2011 , 86, 615-7	4
1647	Proportions of bone marrow lymphocyte subsets at diagnosis may predict survival in patients with newly diagnosed diffuse large B-cell lymphoma independently of the international prognostic index. 2011 , 86, 622-4	
1646	Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. 2011 , 86, 627-30	9
1645	Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. 2011 , 86, 625-7	7
1644	Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. 2011 , 86, 610-1	61
1643	Utility of positron emission tomography scans in mantle cell lymphoma. 2011 , 86, 841-5	50
1642	Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma--a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography. 2011 , 24, 1181-90	63
1641	Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 2011 , 117, 1010-8	51
1640	Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongermlinal center B-cell-like than in germinal center B-cell-like phenotype. 2011 , 117, 5058-66	226
1639	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. 2011 , 29, 38-41	23

1638	A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma. 2011 , 29, 151-3	
1637	Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan. 2011 , 29, 131-8	4
1636	Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study. 2011 , 79, 823-8	20
1635	External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma. 2011 , 79, 1124-30	18
1634	Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. 2011 , 80, 1164-70	26
1633	Peripheral T-cell lymphoma--not otherwise specified. 2011 , 79, 321-9	53
1632	Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. 2011 , 35, 358-62	16
1631	Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. 2011 , 52, 690-6	57
1630	Response to treatment series: part 2, tumor response assessment--using new and conventional criteria. 2011 , 197, 18-27	56
1629	Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. 2011 , 196, 662-9	95
1628	End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. 2011 , 22, 910-915	76
1627	Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. 2011 , 52, 317-20	3
1626	T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. 2011 , 52, 214-22	14
1625	Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network. 2011 , 52, 1920-8	20
1624	Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. 2011 , 46, 393-9	21
1623	[Radiological evaluation of tumor response in oncological studies (tumor response evaluation)]. 2011 , 183, 695-703	7
1622	A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. 2011 , 118, 5119-25	152
1621	Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. 2011 , 52, 597-603	42

1620	Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. 2011 , 52, 1668-74		50
1619	Pretreatment serum level of 15-kDa granulysin might have a prognostic value in patients with diffuse large B cell lymphoma. 2011 , 126, 79-86		4
1618	The role of PET and PET/CT in managing the care of lymphoma patients. 2011 , 39, 190-4		6
1617	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). 2011 , 22, 689-695		56
1616	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2011 , 22 Suppl 6, vi55-8		80
1615	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2011 , 22 Suppl 6, vi59-63		63
1614	SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. 2011 , 118, 37-43		235
1613	Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. 2011 , 186, 6044-55		77
1612	A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. 2011 , 52, 1898-902		29
1611	18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. 2011 , 52, 386-92		133
1610	CD23 expression in follicular lymphoma: clinicopathologic correlations. 2011 , 135, 46-53		27
1609	Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography. 2011 , 2011, 271595		9
1608	Revisiting the Marrow Metabolic Changes after Chemotherapy in Lymphoma: A Step towards Personalized Care. 2011 , 2011, 942063		3
1607	Meta-analyses of early-stage hodgkin lymphoma. 2011 , 125, 32-8		7
1606	High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. 2011 , 126, 44-51		36
1605	Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma. 2011 , 3, e26		9
1604	Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3023-9	2.2	58
1603	Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3194-200	2.2	148

1602	Interindividual variability of response to rituximab: from biological origins to individualized therapies. 2011 , 17, 19-30		69
1601	Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1620-6	2.2	56
1600	Comparison of four prognostic scores in peripheral T-cell lymphoma. 2011 , 22, 397-404		65
1599	Relapsed/refractory diffuse large B-cell lymphoma. 2011 , 2011, 498-505		296
1598	Targeted-therapy and imaging response: a new paradigm for clinical evaluation?. 2011 , 6, 259-65		18
1597	Optimal therapy of advanced Hodgkin lymphoma. 2011 , 2011, 310-6		17
1596	Positron emission tomography in the management of Hodgkin lymphoma. 2011 , 2011, 317-22		18
1595	Clinical end points and response criteria in mycosis fungoides and S�ary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2598-607	2.2	407
1594	Beyond chemotherapy: new agents for targeted treatment of lymphoma. 2011 , 8, 85-96		70
1593	Brentuximab vedotin for the treatment of CD30+ lymphomas. 2011 , 3, 475-85		34
1592	Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. 2011 , 25, 1877-81		86
1591	Objective assessment of tumour response to therapy based on tumour growth kinetics. 2011 , 105, 682-6		19
1590	Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas. 2011 , 11, 31-40		3
1589	Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. 2011 , 7, 9-14		4
1588	The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. 2011 , 117, 2807-12		156
1587	Magnetic resonance imaging of malignant lymphoma. 2011 , 4, 161-71		15
1586	Computational approaches to assist in the evaluation of cancer treatment response. 2011 , 3, 233-246		3
1585	PET/CT en oncolog�a pedi�rica. 2011 , 22, 528-537		

1584	Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. 2011 , 103, 1799-806	112
1583	Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. 2011 , 22, 1392-1403	35
1582	Hodgkin's Disease in Patients with HIV Infection. 2011 , 2011,	24
1581	Therapy of newly diagnosed follicular lymphoma. 2012 , 2, 188	
1580	Usefulness of flow cytometric immunophenotyping for bone marrow staging in patients with mantle cell lymphoma after therapy. 2012 , 137, 634-40	2
1579	Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. 2012 , 91, 1-9	131
1578	Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. 2012 , 23, 2695-2703	51
1577	The diagnostic value of FDG-PET cannot be judged by iliac bone marrow biopsy. 2012 , 85, 1204-5; author reply 1206-7	1
1576	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. 2012 , 17, 239-49	85
1575	Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. 2012 , 53, 263-9	21
1574	Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. 2012 , 17, 1073-80	36
1573	Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. 2012 , 23, 1280-1286	34
1572	Advances in the treatment of relapsed or refractory Hodgkin's lymphoma. 2012 , 17, 367-76	12
1571	Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. 2012 , 3, 227-35	8
1570	U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. 2012 , 18, 5845-9	169
1569	Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3848-53	2.2 92
1568	Chemotherapy alone for localized diffuse large B-cell lymphoma. 2012 , 18, 421-6	19
1567	Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. 2012 , 53, 922-7	57

1566	Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4161-7	2.2	123
1565	Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3460-7	2.2	494
1564	A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by $\alpha^{\text{CD}20}$ -ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 2012 , 23, 415-20		24
1563	Perfusion and flow extraction product as potential discriminators in untreated follicular and diffuse large B cell lymphomas using volume perfusion CT with attempt at histopathologic explanation. 2012 , 198, 1239-46		10
1562	Radiologische Evaluation des Tumoransprechens in onkologischen Therapiestudien (Tumor Response Evaluation). 2012 , 33, 103-111		
1561	MSCT follow-up in malignant lymphoma: comparison of manual linear measurements with semi-automated lymph node analysis for therapy response classification. 2012 , 184, 795-804		6
1560	The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies. 2012 , 53, 2166-74		12
1559	Interim response assessment for Hodgkin lymphoma: size matters. 2012 , 53, 2095-6		
1558	Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. 2012 , 97, 410-5		45
1557	Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. 2012 , 53, 2143-50		45
1556	[Application of MR/PET in oncologic imaging]. 2012 , 184, 780-7		11
1555	Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study. 2012 , 262, 956-68		47
1554	EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. 2012 , 25, 968-82		140
1553	Clinical utility of ^{18}F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma. 2012 , 85, e490-6		32
1552	Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. 2012 , 120, 560-8		140
1551	Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2197-203	2.2	215
1550	Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010. 2012 , 28, 798-805		15
1549	Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. 2012 , 53, 34-42		35

1548	How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?. 2012 , 2, e93	11
1547	Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. 2012 , 53, 1244-52	131
1546	Lymphoma study group of JCOG. 2012 , 42, 85-95	21
1545	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. 2012 , 23, 729-735	17
1544	Diagnosis and treatment of diffuse large B-cell lymphoma. 2012 , 142, w13511	21
1543	Assessment of Response to Therapy. 2012 , 279-322	2
1542	Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. 2012 , 47, 1082-6	13
1541	Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. 2012 , 97, 262-9	151
1540	18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma. 2012 , 2012, 456706	3
1539	Positron emission tomography in lymphoma: Fine tuning of international harmonization project. 2012 , 20, 17-23	
1538	Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. 2012 , 53, 807-11	11
1537	Clinical Trials and Treatment of ATL. 2012 , 2012, 101754	26
1536	Lenalidomide in diffuse large B-cell lymphoma. 2012 , 2012, 861060	14
1535	Sjögren's Syndrome. 2012 ,	7
1534	Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma. 2012 , 12, 403-8	31
1533	Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. 2012 , 53, 1461-8	7
1532	Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience. 2012 , 17, 76-84	21
1531	Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead. 2012 , 96, 261-71	46

1530	Brown fat at PET/CT: correlation with patient characteristics. 2012 , 263, 836-42		53
1529	Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3368-75	2.2	128
1528	Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. 2012 , 198, 737-45		138
1527	Positron emission tomography oncology research in the UK: a comparison with USA and Europe. 2012 , 33, 341-8		3
1526	Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. 2012 , 26, 861-5		14
1525	Roles and limitations of FDG PET in pediatric non-Hodgkin lymphoma. 2012 , 37, 656-62		16
1524	Non-Hodgkin's lymphoma involving the ileocecal region: a single-institution analysis of 46 cases in a Chinese population. 2012 , 46, 509-14		14
1523	Comparison between endoscopic macroscopic classification and F-18 FDG PET findings in gastric mucosa-associated lymphoid tissue lymphoma patients. 2012 , 37, 152-7		13
1522	Histiocyte-rich xanthomatous pseudotumor mimicking relapse on positron emission tomography imaging in an adolescent with primary mediastinal diffuse large B-cell lymphoma. 2012 , 34, 232-5		11
1521	Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience. 2012 , 28, 835-40		14
1520	Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. 2012 , 97, 1523-31		100
1519	Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. 2012 , 97, 416-22		58
1518	Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. 2012 , 120, 1581-8		202
1517	Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. 2012 , 119, 6373-8		86
1516	Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. 2012 , 119, 2644-56		316
1515	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. 2012 , 119, 3940-50		396
1514	Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. 2012 , 119, 4115-22		104
1513	Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. 2012 , 119, 4129-32		59

1512	Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. 2012 , 119, 6379-81		108
1511	Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. 2012 , 120, 4256-62		101
1510	Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. 2012 , 379, 1791-9		446
1509	Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma. 2012 , 47, 1397-402		16
1508	Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. 2012 , 53, 1469-73		20
1507	HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4111-6	2.2	111
1506	Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2190-6	2.2	759
1505	A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. 2012 , 53, 1299-1305		10
1504	Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2183-9	2.2	1091
1503	Guidelines for the investigation and management of mantle cell lymphoma. 2012 , 159, 405-26		61
1502	Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4317-22	2.2	140
1501	Imaging follicular lymphoma using positron emission tomography with [(18)F]fluorodeoxyglucose: to what purpose?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4285-7	2.2	9
1500	Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4508-14	2.2	191
1499	Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. 2012 , 39, 643-59		118
1498	Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2820-2	2.2	160
1497	Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. 2012 , 53, 2378-82		50
1496	Hodgkin's lymphoma in adults. 2012 , 380, 836-47		96
1495	Non-Hodgkin lymphoma. 2012 , 380, 848-57		401

1494	Linfomas no Hodgkin: diagnóstico y tratamiento. 2012 , 16, 1-6	
1493	[Bone marrow histology from the clinical point of view]. 2012 , 33, 490-5	1
1492	Radiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma. 2012 , 22, 1946-54	57
1491	Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. 2012 , 83, e647-54	12
1490	Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results. 2012 , 31, 135-41	3
1489	Unusual presentation of sarcoid-like reaction on bone marrow level associated with mediastinal lymphadenopathy on (18)F-FDG-PET/CT resembling an early recurrence of Hodgkin's Lymphoma. 2012 , 31, 207-9	6
1488	18F-FDG-PET/CT in lymphoma: two decades of experience. 2012 , 31, 340-9	4
1487	Usefulness of (18)F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin's Lymphoma. 2012 , 46, 269-77	13
1486	A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. 2012 , 18, 248-55	190
1485	Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. 2012 , 120, 1470-2	69
1484	Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. 2012 , 53, 862-7	44
1483	Review of Clinical Applications of Fluorodeoxyglucose-PET/Computed Tomography in Pediatric Patients with Lymphoma. 2012 , 7, 47-56	4
1482	[Role of FDG-PET scanning in stage IIIAN2 non-small cell lung cancer]. 2012 , 29, 149-60	0
1481	Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results. 2012 , 31, 135-141	
1480	The Evolving Role of Medical Imaging in Lymphoma Management: The Clinician's Perspective. 2012 , 7, 35-46	0
1479	Role of Positron Emission Tomography with Fluorodeoxyglucose F 18 in Personalization of Therapy in Patients with Lymphoma. 2012 , 7, 57-65	0
1478	Role of Structural Imaging in Lymphoma. 2012 , 7, 1-19	4
1477	My treatment approach to patients with diffuse large B-cell lymphoma. 2012 , 87, 161-71	49

1476	Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. 2012 , 53, 1757-63		9
1475	Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. 2012 , 53, 801-6		6
1474	Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. 2012 , 53, 64-70		51
1473	Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era. 2012 , 53, 381-5		37
1472	Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. 2012 , 53, 43-9		30
1471	Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Mantle Cell Lymphoma Group. 2012 , 53, 1033-6		14
1470	Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab. 2012 , 42, 1035-42		16
1469	Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. 2012 , 119, 2066-73		186
1468	Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. 2012 , 53, 1945-8		10
1467	The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. 2012 , 53, 575-80		67
1466	Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2776-82	2.2	147
1465	Head and Neck Cancer Imaging. 2012 ,		12
1464	Spleen in haematological malignancies: spectrum of imaging findings. 2012 , 85, 81-92		74
1463	Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. 2012 , 97, 1073-9		88
1462	Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012 , 23 Suppl 7, vii78-82		100
1461	Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. 2012 , 119, 6145-54		87
1460	SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. 2012 , 120, 2973-80		277
1459	Intérêt de la TEP dans le bilan d'extension et l'évaluation de la maladie résiduelle des lymphomes testiculaires : étude rétrospective. 2012 , 36, 268-277		

1458	High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. 2012 , 18, 788-93	77
1457	Therapeutic strategies in elderly and very elderly patients. 2012 , 25, 91-100	6
1456	Size and attenuation CT (SACT) of residual masses in patients with follicular non-Hodgkin lymphoma: more than a status quo?. 2012 , 81, 1657-61	2
1455	A comparative study: diffusion weighted whole body imaging with background body signal suppression and hybrid Positron Emission Computed Tomography on detecting lesions in oncologic clinics. 2012 , 81, 1662-6	9
1454	Mucosa-associated lymphoid tissue lymphoma of the salivary glands: MR imaging findings including diffusion-weighted imaging. 2012 , 81, e612-7	27
1453	Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. 2012 , 21, 205-16	59
1452	Novel therapeutic agents for cutaneous T-Cell lymphoma. 2012 , 5, 24	36
1451	Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. 2012 , 42, 1113-9	20
1450	Residual Disease Assessment and Its Role in Monitoring Lymphoid and Plasma Cell Neoplasms. 2012 , 83-95	
1449	The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. 2012 , 47, 957-66	61
1448	PET for Measuring Therapy Response After Radionuclide Therapy. 2012 , 917-929	
1447	Advances in oncologic imaging: update on 5 common cancers. 2012 , 62, 364-93	44
1446	The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. 2012 , 91, 1731-9	25
1445	A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies. 2012 , 12, 330-6	28
1444	Considerations in the initial management of follicular lymphoma. 2012 , 9, S53-S60	6
1443	Integration of cell biology, pharmacological modeling and statistical analysis: part I: cell biology and PK/PD in the Oncology paradigm. 2012 , 83, 153-69	1
1442	Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. 2012 , 48, 3319-27	104
1441	Copper levels in patients with hematological malignancies. 2012 , 23, 738-41	29

1440 PET-MRI in oncology. **2012**, 36, 459-461

1439 Comparaison de l'IRM de diffusion et de la TEP/TDM au FDG dans le bilan des lymphomes. **2012**, 36, 504-512

1438 Promise and pitfalls of quantitative imaging in oncology clinical trials. **2012**, 30, 1301-12 62

1437 Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?. **2012**, 7, 193-9 22

1436 Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. **2012**, 29, 3535-9 6

1435 Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. **2012**, 26, 616-21 23

1434 Unusual presentation of sarcoid-like reaction on bone marrow level associated with mediastinal lymphadenopathy on 18F-FDG-PET/CT resembling an early recurrence of Hodgkin's Lymphoma. **2012**, 31, 207-209

1433 Positron emission tomographic scans in lymphoma: convention and controversy. **2012**, 87, 571-80 44

1432 18F-FDG-PET/CT in lymphoma: Two decades of experience. **2012**, 31, 340-349

1431 CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. **2012**, 91, 1897-906 14

1430 Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation. **2012**, 91, 1907-15 6

1429 A unique pattern of extranodal involvement in Korean adults with sporadic Burkitt lymphoma: a single center experience. **2012**, 91, 1917-22 17

1428 Assessing Response to Therapy. **2012**, 25-33

1427 Hematologic Malignancy: The Lymphomas. **2012**, 531-553 1

1426 Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma. **2012**, 117, 1250-63 7

1425 Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma. **2012**, 30, 642-7 3

1424 High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. **2012**, 18, 1677-86 35

1423 Bone Marrow Lymphoid Infiltrates. **2012**, 1

1422	Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. 2012 , CD009045	4
1421	Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma. 2012 , 91, 1393-401	23
1420	Lymphoma. 329-365	
1419	Malignancy of unknown origin. 445-465	
1418	Methodological aspects of therapeutic response evaluation with FDG-PET. 487-500	
1417	FDG-PET in Follicular Lymphoma Management. 2012 , 2012, 370272	11
1416	Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support. 2012 , 543-550	
1415	Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. 2012 , 47, 8-16	6
1414	Aggressive chemotherapy in frail patients with diffuse large B-cell lymphoma: The role of pegylated liposomal doxorubicin. 2012 , 2,	
1413	Hematology. 2012 , 211-227	
1412	Treatment of Early Stage Hodgkin Lymphoma. 2012 ,	
1411	Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. 2012 , 3, 304-308	5
1410	Clinical significance of standardized uptake value and maximum tumor diameter in patients with primary extranodal diffuse large B cell lymphoma. 2012 , 47, 207-12	9
1409	Clinical characteristics and outcomes of primary bone lymphoma in Korea. 2012 , 47, 213-8	11
1408	Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer. 2012 , 12, 212-24	7
1407	Prognostic assessment in patients with indolent B-cell lymphomas. 2012 , 2012, 107892	8
1406	Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy. 2012 , 5, 10	1
1405	Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. 2012 , 91, 715-721	18

1404	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. 2012 , 119, 2709-20	1110
1403	Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. 2012 , 91, 1579-86	25
1402	Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. 2012 , 30, 194-9	12
1401	Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma. 2012 , 30, 214-5	2
1400	Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype. 2012 , 30, 8-12	5
1399	Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma. 2012 , 33, 1733-8	6
1398	Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. 2012 , 87, 663-8	97
1397	Dexrazoxane does not affect treatment outcome in non-Hodgkin's lymphoma patients. 2012 , 87, 830-2	3
1396	The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. 2012 , 87, 937-40	35
1395	A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. 2012 , 118, 3128-34	80
1394	A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. 2012 , 118, 3538-48	16
1393	Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. 2012 , 118, 3565-70	37
1392	A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. 2012 , 118, 4706-14	84
1391	Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. 2012 , 118, 5270-7	112
1390	The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. 2012 , 30, 631-7	549
1389	[Response criteria for malignant lymphoma]. 2012 , 52, 330-7	1
1388	FDG PET/CT predictive role in follicular lymphoma. 2012 , 39, 864-71	28
1387	Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. 2012 , 91, 687-695	69

1386	Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. 2012 , 91, 697-703	106
1385	Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. 2012 , 69, 1165-72	17
1384	Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy. 2012 , 156, 142-3	9
1383	Burkitt lymphoma: staging and response evaluation. 2012 , 156, 761-5	26
1382	Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. 2012 , 40, 359-66	6
1381	A real-time (PCR) for a real life—Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice. 2012 , 40, 528-539.e4	2
1380	Mantle cell lymphoma. 2012 , 82, 78-101	52
1379	IN6 Moving forward a more cost-effective therapy of Hodgkin's lymphoma. 2012 , 82, S3-S4	
1378	Clinical features and prognostic model for extranasal NK/T-cell lymphoma. 2012 , 89, 103-10	44
1377	Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. 2012 , 36, 709-14	8
1376	Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma. 2012 , 103, 477-82	50
1375	The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. 2012 , 73, 846-54	24
1374	Management of children with high-risk Hodgkin lymphoma. 2012 , 157, 3-13	21
1373	Incidence, risk factors and outcome of histological transformation in follicular lymphoma. 2012 , 157, 188-96	75
1372	Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. 2012 , 157, 321-30	56
1371	Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. 2012 , 157, 543-52	11
1370	Phase II study of sorafenib in patients with relapsed or refractory lymphoma. 2012 , 158, 108-19	33
1369	Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. 2012 , 158, 355-62	198

1368	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. 2012 , 10, 18	18
1367	A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved. 2012 , 87, 32-6	26
1366	Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. 2012 , 87, 258-65	28
1365	Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. 2012 , 87, 479-83	11
1364	Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma. 2012 , 62, 257-65	27
1363	Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. 2012 , 39, 4-12	102
1362	Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. 2012 , 91, 375-82	19
1361	High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. 2013 , 31, 34-40	15
1360	Diffuse large B-cell lymphoma of the ocular adnexal region: a nation-based study. 2013 , 91, 163-9	20
1359	Cellular immunotherapy for refractory hematological malignancies. 2013 , 11, 150	25
1358	Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results. 2013 , 8, 152	22
1357	Assessing the effectiveness of a Grand Rounds CME activity for health-care professionals. 2013 , 28, 591-6	1
1356	Potential Clinical Applications of PET/Magnetic Resonance Imaging. 2013 , 8, 367-84	3
1355	Available evidence and outcome of off-label use of rituximab in clinical practice. 2013 , 69, 1689-99	8
1354	PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. 2013 , 43, 860-75	113
1353	PET/computed tomography and lymphoma. 2013 , 51, 833-44	6
1352	A radiologist's guide to treatment response criteria in oncologic imaging: functional, molecular, and disease-specific imaging biomarkers. 2013 , 201, 246-56	14
1351	Bendamustine salvage therapy for T cell neoplasms. 2013 , 92, 1249-54	25

1350	Adults with Palpable Neck Mass: Evidence-Based Neuroimaging. 2013 , 641-677	1
1349	Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma. 2013 , 13, 222	33
1348	A multicenter, open-label, noncomparative screening study of enzastaurin in adult patients with non-Hodgkin lymphomas. 2013 , 13, 398-403	1
1347	Non-Hodgkin Lymphoma. 2013 ,	1
1346	T-Cell Lymphomas. 2013 ,	1
1345	Burkitt's Lymphoma. 2013 ,	1
1344	Increased expression of the spindle checkpoint protein BubR1 is associated with high cell proliferation in primary gastrointestinal diffuse large B cell lymphoma. 2013 , 66, 747-52	4
1343	Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP. 2013 , 97, 397-402	9
1342	The role of maintenance strategies in lymphoma and CLL?. 2013 , 6, 102-108	
1341	A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. 2013 , 6, 44	53
1340	Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on ¹⁸ F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. 2013 , 40, 1321-9	59
1339	Imaging characteristics of cardiac dominant diffuse large B-cell lymphoma demonstrated with MDCT and PET/CT. 2013 , 40, 1337-44	27
1338	An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and SUVmax. 2013 , 40, 1312-20	195
1337	The impact of coaxial core biopsy guided by FDG PET/CT in oncological patients. 2013 , 40, 98-103	50
1336	Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era. 2013 , 92, 1513-20	14
1335	Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. 2013 , 92, 1503-11	13
1334	Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era. 2013 , 92, 1495-501	4
1333	Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. 2013 , 92, 1529-36	58

1332	The role of ^{18}F -fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkin's lymphoma patients. 2013 , 92, 1369-77	8
1331	DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. 2013 , 92, 1041-8	14
1330	Maximum standard uptake value of ^{18}F -fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma. 2013 , 92, 239-44	21
1329	Using a cut-off SUV level to define bone marrow lesions on FDG PET is not appropriate. 2013 , 92, 283-4	4
1328	Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. 2013 , 72, 241-9	9
1327	PET/CT in Oncology: Current Status and Perspectives. 2013 , 1, 177-190	53
1326	60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. 2013 ,	7
1325	Whole-body PET/MRI in oncology: current status and clinical applications. 2013 , 1, 31-44	35
1324	A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma. 2013 , 54, 1921-7	2
1323	A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas. 2013 , 31, 1514-21	8
1322	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. 2013 , 119, 1195-202	117
1321	Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. 2013 , 27, 1902-9	153
1320	Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo $^{\text{TM}}$) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. 2013 , 162, 631-8	22
1319	[Criteria for radiological assessment of therapy response: criteria-based appraisal]. 2013 , 53, 322-8	
1318	Bilan d'extension et suivi dans le traitement des lymphomes. 2013 , 94, 150-163	
1317	Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. 2013 , 19, 746-53	65
1316	Response criteria in oncologic imaging: review of traditional and new criteria. 2013 , 33, 1323-41	189
1315	Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. 2013 , 369, 507-16	1139

1314	Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. 2013 , 163, 611-20		20
1313	Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. 2013 , 87, 311-6		33
1312	Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features. 2013 , 91 Thesis 5, 1-27		27
1311	An update on criteria for assessing tumor response to treatment. 2013 , 42, 209-19		1
1310	Application of PET and PET-CT in Peritoneal Imaging. 2013 , 1541-1562		2
1309	Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4199-206	2.2	384
1308	Open questions in the management of mantle cell lymphoma. 2013 , 39, 602-9		9
1307	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. 2013 , 14, 1348-56		212
1306	Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. 2013 , 14, e548-61		17
1305	Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma. 2013 , 13, 657-63		10
1304	Update on pediatric leukemia and lymphoma imaging. 2013 , 34, 578-99		16
1303	PET/CT in malignant lymphoma: basic information, clinical application, and proposal. 2013 , 98, 398-405		10
1302	Evaluation of imaging findings differentiating extranodal non-Hodgkin's lymphoma from squamous cell carcinoma in naso- and oropharynx. 2013 , 37, 657-63		20
1301	Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. 2013 , 28, 471-8		17
1300	Anthracycline-containing regimens for treatment of follicular lymphoma in adults. 2013 , CD008909		3
1299	Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. 2013 , 19, 934-9		20
1298	Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. 2013 , 19, 410-7		54
1297	Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group. 2013 , 98, 463-71		3

1296	Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement. 2013 , 6, 76	13
1295	Development of IgG4-related disease 10 years after chemotherapy for diffuse large B cell lymphoma and longstanding bronchial asthma. 2013 , 98, 122-8	12
1294	Lymphomes non hodgkiniens primitifs du cavum : ^propos de 32 cas pris en charge ^lâInstitut national dâncologie (Rabat, Maroc) entre 1997 et 2009. 2013 , 5, 51-56	
1293	(18)F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase. 2013 , 47, 249-56	6
1292	Diagnosing celiac disease in patients with a history of lymphoma: factors that matter. 2013 , 125, 696-703	
1291	Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma. 2013 , 54, 714-9	12
1290	Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. 2013 , 54, 1183-7	37
1289	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. 2013 , 54, 62-8	13
1288	Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. 2013 , 54, 2627-30	5
1287	High dose cytarabine with rituximab is an effective first-line therapy for mantle cell lymphoma and produces ample stem cell harvest yields after multiple chemotherapy cycles. 2013 , 54, 2303-5	3
1286	Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. 2013 , 91, 122-8	22
1285	A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. 2013 , 119, 1683-9	8
1284	Phase I study of a modified regimen of âBttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. 2013 , 28, 370-9	2
1283	The risk of CNS involvement in aggressive lymphomas in the rituximab era. 2013 , 6, 643-52	1
1282	International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. 2013 , 54, 683-90	224
1281	Response assessment in lymphoma: time to lower the bar?. 2013 , 54, 673-4	1
1280	Combination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large B-cell lymphoma: a case report. 2013 , 54, 2553-5	3
1279	Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). <i>Journal of Clinical Oncology</i> , 2013 , 31, 3061-8	2.2 304

1278	Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation. 2013 , 121, 840-8		21
1277	Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. <i>Journal of Clinical Oncology</i> , 2013 , 31, 314-20	2.2	138
1276	Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 565-72	2.2	161
1275	Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma. 2013 , 54, 2645-53		10
1274	Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. 2013 , 54, 1915-20		12
1273	Are we ready for positron emission tomography/computed tomography-based target volume definition in lymphoma radiation therapy?. 2013 , 85, 14-20		9
1272	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). 2013 , 24, 561-76		162
1271	Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 456-60	2.2	144
1270	SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. 2013 , 88, 185-92		28
1269	Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. 2013 , 54, 277-83		39
1268	Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. 2013 , 152, 714-26		1006
1267	Hodgkin lymphoma. 2013 , 85, 216-37		77
1266	Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate. 2013 , 33, 93-104		45
1265	Diffuse large B-cell lymphoma. 2013 , 87, 146-71		240
1264	Staging and monitoring in the treatment of lymphomas. 2013 , 94, 145-57		8
1263	Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma. 2013 , 109, 133-9		18
1262	Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. 2013 , 19, 1368-73		24
1261	Stage IE/IIe extranodal NK/T-cell lymphoma arising in the nasal cavity: analysis of CT findings and their prognostic value. 2013 , 68, e384-90		10

1260	Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. 2013 , 19, 82-6	5
1259	Intégration des critères métaboliques de la TEP au 18FDG pour le choix des lésions cibles en imagerie onco-hématologique. 2013 , 37, 244-250	
1258	Quantitative and qualitative evaluation of the interim PET/CT in lymphoma treatment in the prediction of complete metabolic response. 2013 , 32, 70-76	
1257	FDG-PET in the evaluation of myeloma in 2012. 2013 , 94, 184-9	5
1256	Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. 2013 , 54, 2606-12	8
1255	Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. 2013 , 86, 569-77	54
1254	Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 2013 , 13, 258-65	13
1253	Specific features identify patients with relapsed or refractory mantle cell lymphoma benefiting from autologous hematopoietic cell transplantation. 2013 , 19, 1403-6	22
1252	A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment. 2013 , 4, 242-8	23
1251	Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies. 2013 , 13, 385-91	28
1250	Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. 2013 , 19, 1087-93	11
1249	Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. 2013 , 13, 410-6	18
1248	[Quantitative and qualitative evaluation of the interim PET/CT in lymphoma treatment in the prediction of complete metabolic response]. 2013 , 32, 70-6	2
1247	La TEP au FDG dans l'évaluation du myélome en 2012. 2013 , 94, 190-195	
1246	Treatment for patients with indolent and mantle cell lymphoma. 2013 , 382, 1093-4	
1245	Actualización en linfomas primarios de mama: serie de casos y revisión de la literatura. 2013 , 56, 436-441	0
1244	Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma. 2013 , 30, 339	13
1243	Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma. 2013 , 30, 350	9

1242	Brentuximab vedotin. 2013 , 19, 22-7	108
1241	Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. 2013 , 160, 47-52	59
1240	Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma. 2013 , 160, 510-4	12
1239	Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. <i>Journal of Clinical Oncology</i> , 2013 , 31, e59-63	2.2 53
1238	Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. 2013 , 54, 2144-8	27
1237	Diagnosis and Treatment of Non-Hodgkinâs Lymphoma of Adults. 2013 , 1027-1047	
1236	Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. 2013 , 368, 1408-16	388
1235	Therapeutic Approaches to Burkittâs Lymphoma. 2013 , 251-268	1
1234	R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. 2013 , 161, 383-8	19
1233	FDG PET and PET/CT. 2013 , 187, 351-69	39
1232	The Role of Imaging in Nuclear Medicine: The Medical Perspective. 2013 , 7-18	
1231	Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. 2013 , 54, 2399-404	23
1230	Ocular adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor. 2013 , 23, 344-55	49
1229	The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). 2013 , 54, 1405-10	21
1228	Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials. 2013 , 49, 769-81	40
1227	The imaging viewpoint: how imaging affects determination of progression-free survival. 2013 , 19, 2621-8	15
1226	Pharmacogenetic analysis in the treatment of Hodgkin lymphoma. 2013 , 54, 1706-12	3
1225	High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma. 2013 , 54, 2620-6	4

1224	Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low-dose CT. 2013 , 43, 86-92		17
1223	Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma. 2013 , 54, 2122-30		10
1222	Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. 2013 , 369, 32-42		1656
1221	The role of hematopoietic SCT in adult Burkitt lymphoma. 2013 , 48, 617-29		2
1220	End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. 2013 , 19, 6566-77		19
1219	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1506-13	2.2	193
1218	A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. 2013 , 31, 355-62		23
1217	Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. 2013 , 54, 1026-31		64
1216	Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age. 2013 , 13, 404-9		5
1215	Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma. 2013 , 13, 253-7		8
1214	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. 2013 , 98, 255-63		125
1213	Quantification of dose nonuniformities by voxel-based dosimetry in patients receiving 90Y-ibritumomab-tiuxetan. 2013 , 28, 98-107		6
1212	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. 2013 , 98, 1554-62		165
1211	Mantle Cell Lymphoma. 2013 , 157-175		
1210	Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. <i>Journal of Clinical Oncology</i> , 2013 , 31, 88-94	2.2	858
1209	MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. 2013 , 26, 171-81		15
1208	Rituximab in the treatment of diffuse large B-cell lymphoma primary of the lung. 2013 , 18, 81-4		8
1207	Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab: a single-center experience. 2013 , 18, 74-80		4

1206 PET imaging. **2013**, 96-108

1205 The incidence of secondary central nervous system involvement in patients with non-Hodgkin's lymphoma as detected by 18F-FDG PET/CT. **2013**, 34, 50-6 12

1204 Long-term outcome of primary endocrine non-Hodgkin lymphomas: does the site make the difference?. **2013**, 106, 623-30 4

1203 Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI. **2013**, 201, 1115-9 55

1202 The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma. **2013**, 9, 807-15 3

1201 Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. **2013**, 98, 1232-6 57

1200 CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. **2013**, 98, 1250-8 43

1199 Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. **2013**, 24, 1385-92 82

1198 Bildgebende Beurteilung des Therapieansprechens unter Chemotherapie. **2013**, 13, 221-239 0

1197 PET/CT zur Therapiekontrolle beim Hodgkin-Lymphom des Erwachsenen: Hängt die Indikation zur Strahlentherapie vom Ergebnis der PET/CT ab?. **2013**, 36, 86-91 1

1196 Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. **2013**, 54, 483-90 12

1195 Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. **2013**, 54, 497-502 13

1194 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. **2013**, 54, 2163-7 48

1193 Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. **2013**, 54, 2093-5 3

1192 Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma. **2013**, 48, 1212-7 27

1191 Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response. **2013**, 48, 1484-5 7

1190 Para-aortic lymphoma simulating mycotic abdominal aortic aneurysm. **2013**, 128, 674-5 9

1189 FDG-PET/CT in lymphoma. **2013**, 23, 354-65 25

1188	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. 2013 , 24, 2108-12		104
1187	First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. 2013 , 19, 5494-504		38
1186	Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2974-6	2.2	11
1185	Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?. 2013 , 54, 1082-93		39
1184	Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogeneously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment. 2013 , 34, 946-52		25
1183	Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis. 2013 , 59, 280-9		4
1182	The metabolism of lymphomas. 2013 , 20, 345-54		14
1181	An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. 2013 , 24, 3065-9		35
1180	Reporting guidance for oncologic 18F-FDG PET/CT imaging. 2013 , 54, 756-61		21
1179	Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. 2013 , 5, 5-11		50
1178	Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. 2013 , 57, 794-802		150
1177	Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. 2013 , 66, 956-61		14
1176	Overview: progression-free survival as an endpoint in clinical trials with solid tumors. 2013 , 19, 2607-12		44
1175	Comparison of the efficacy and safety of Rituximab (Mabthera®) and its biosimilar (Reditux®) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis. 2013 , 34, 292-8		31
1174	Prognostic significance of pretreatment 18F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using 131I-rituximab. 2013 , 130, 74-82		12
1173	Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1442-9	2.2	137
1172	Successive B-cell lymphomas mostly reflect recurrences rather than unrelated primary lymphomas. 2013 , 140, 114-26		12
1171	Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas. 2013 , 54, 507-15		29

1170	In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. 2013 , 54, 1244-50	126
1169	Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. 2013 , 98, 620-5	11
1168	Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma. 2013 , 130, 305-11	17
1167	Peripheral T-cell lymphoma in HIV-infected patients: a study of 17 cases in the combination antiretroviral therapy era. 2013 , 161, 843-51	6
1166	Prognostic impact of monocyte count at presentation in mantle cell lymphoma. 2013 , 162, 465-73	36
1165	Fluoro-deoxy-glucose positron emission tomography/computed tomography in lymphoma: A pictorial essay. 2013 , 28, 85-92	1
1164	State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response". 2013 , 3, 212	26
1163	Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. 2013 , 162, 138-41	29
1162	Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation. 2013 , 2013, 658371	15
1161	Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. 2013 , 70, 589-97	29
1160	Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. 2013 , 88, E273-6	9
1159	Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. 2013 , 98, 615-9	46
1158	A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. 2013 , 163, 334-42	33
1157	Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. 2013 , 88, 890-4	86
1156	Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. 2013 , 31, 151-5	7
1155	A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. 2013 , 119, 3797-804	37
1154	Absolute monocyte count at diagnosis and survival in mantle cell lymphoma. 2013 , 163, 545-7	12
1153	Advanced MR techniques in multicenter clinical trials. 2013 , 37, 761-9	11

1152	Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2103-9	2.2	126
1151	Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP. 2013 , 104, 1245-51		11
1150	Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. 2013 , 88, 400-5		76
1149	Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 2013 , 31, 183-8		25
1148	Comparison of different MRI sequences in lesion detection and early response evaluation of diffuse large B-cell lymphoma--a whole-body MRI and diffusion-weighted imaging study. 2013 , 26, 1186-94		21
1147	Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. 2013 , 119, 3318-25		5
1146	Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. 2013 , 122, 2104-13		42
1145	A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. 2013 , 19, 6624-32		31
1144	Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies. 2013 , 27, 1920-3		18
1143	Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma. 2013 , 3, e110		18
1142	A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. 2013 , 109, 2560-5		6
1141	Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. 2013 , 54, 2631-8		30
1140	Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma. 2013 , 14, 515-23		6
1139	Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. 2013 , 19, 6882-90		88
1138	Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. <i>Journal of Clinical Oncology</i> , 2013 , 31, 592-8	2.2	72
1137	Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1662-8	2.2	136
1136	Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. 2013 , 19, 731-42		81
1135	Low-intensity therapy in adults with Burkitt's lymphoma. 2013 , 369, 1915-25		248

1134	Measuring tumour response: RECIST 1.1 and beyond. 2013 , 22, 20110083	1
1133	Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. 2013 , 122, 499-506	49
1132	CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. 2013 , 121, 4740-8	144
1131	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). 2013 , 122, 1137-43	95
1130	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. 2013 , 122, 1448-54	18
1129	Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. 2013 , 122, 4129-39	445
1128	Abnormal F-18 Fluorodeoxyglucose Uptake of the Lung in Immunocompromised Lymphoma Patients in Complete Remission: Report of Two Cases and Revision of Literature. 2013 , 11, 893-899	1
1127	Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. 2013 , 98, 611-4	81
1126	PET scan integration in lymphoma management. 2013 , 2, 121-135	
1125	MR perfusion imaging in oncology: applications outside the brain. 238-254	
1124	Potential of compressed sensing in quantitative MR imaging of cancer. 2013 , 13, 633-44	13
1123	Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. 2013 , 7, 45-56	13
1122	The Metabolic Signature of Tumors as an Imaging Biomarker in Staging, Restaging and Therapy Response on FDG PET. 2013 , 02,	
1121	Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study. 2013 , 13, 53-62	34
1120	Management of mantle cell lymphoma in the elderly patient. 2013 , 8, 1229-36	9
1119	Analysis of immunoglobulin and T cell receptor gene rearrangement in the bone marrow of lymphoid neoplasia using BIOMED-2 multiplex polymerase chain reaction. 2013 , 10, 1510-7	10
1118	CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma. 2013 , 48, 121-7	8
1117	Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type. 2013 , 48, 274-81	20

1116	Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis. 2013 , 17	1
1115	Predicting tumour response. 2013 , 13, 381-90	6
1114	Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy. 2013 , 6, 23-7	
1113	Case presentation: Nodular sclerosis classical Hodgkin lymphoma bearing Epstein-Barr virus that developed in an older man. 2013 , 16, 119-125	
1112	Positron emission tomography/CT in the management of lymphoma. 2013 , 22, 20110086	1
1111	Matrix metalloproteinase-9 expression by Hodgkin-Reed-Sternberg cells is associated with reduced overall survival in young adult patients with classical Hodgkin lymphoma. 2013 , 8, e74793	3
1110	Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. 2013 , 8, e55870	84
1109	Imaging of musculoskeletal lymphoma. 2013 , 13, 448-57	48
1108	Nóplasies limfoides et mióides. 2013 , 649-683	1
1107	Prognostic factors for lymphomas. 11-31	
1106	Clinical trials in lymphoma. 45-60	
1105	PET ãAssessment of Oncologic Treatment Response. 2013 ,	
1104	The Effect of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients with Ocular Adnexal Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. 2013 , 54, 1157	2
1103	Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component. 2014 , 9, e93903	23
1102	[Quality assessment of radiologic reports of CT examinations for tumor response evaluation]. 2014 , 101, 554-7	
1101	Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy. 2014 , 2014, 368947	2
1100	Profile of pacritinib and its potential in the treatment of hematologic disorders. 2014 , 5, 143-52	16
1099	Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia. 2014 , 7, 1717-22	10

1098	Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma. 2014 , 61, 225-32	19
1097	R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. 2014 , 49, 107-14	9
1096	Unilateral lower extremity swelling as a rare presentation of non-Hodgkin's lymphoma. 2014 , 2014,	3
1095	Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience. 2014 , 49, 170-6	8
1094	Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. 2014 , 49, 15-21	15
1093	Primary mediastinal large B-cell lymphoma: a single-center experience in Korea. 2014 , 49, 36-41	3
1092	Large B cells lymphoma. 2014 , 20, 183-188	
1091	Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection. 2014 , 49, 115-9	2
1090	Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. 2014 , 5, 7368-80	6
1089	High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. 2014 , 55, 2319-27	7
1088	Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma. 2014 , 53, 1093-9	7
1087	Lymphoma: Management Using PET/CT. 2014 , 257-260	
1086	Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. 2014 , 55, 1563-9	5
1085	Hematologic findings predictive of bone marrow disease in dogs with multicentric large-cell lymphoma. 2014 , 43, 505-12	7
1084	Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. 2014 , 55, 802-10	24
1083	The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy. 2014 , 14, 34	15
1082	Evaluation of regional cerebral glucose metabolism in patients with malignant lymphoma of the body using statistical image analysis. 2014 , 28, 950-60	7
1081	Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. 2014 , 32, 1246-57	75

1080	Clinical impact of contrast-enhanced computed tomography combined with low-dose (18)F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management. 2014 , 55, 2887-92	25
1079	Characterization of tissue findings in bone marrow biopsy specimens with small monoclonal B-cell populations. 2014 , 141, 687-96	9
1078	Validity of reduced radiation dose for localized diffuse large B-cell lymphoma showing a good response to chemotherapy. 2014 , 55, 359-63	1
1077	Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. 2014 , 4, e236	40
1076	Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. 2014 , 4, e251	36
1075	In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. 2014 , 27, 1599-611	19
1074	Developments in Statistical Evaluation of Clinical Trials. 2014 ,	1
1073	Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma. 2014 , 55, 2514-9	8
1072	Predictive value of [¹⁸ F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant. 2014 , 55, 276-82	18
1071	Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. 2014 , 55, 1854-60	59
1070	Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. 2014 , 55, 2064-70	17
1069	Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. 2014 , 55, 2312-8	18
1068	Relationship between 2-deoxy-2-[(18)F]-fluoro-d-glucose uptake and clinicopathological factors in patients with diffuse large B-cell lymphoma. 2014 , 55, 520-5	13
1067	Positron Emission Tomography (PET) in Oncology. 2014 , 6, 1821-89	167
1066	Functional Imaging in Lymphoma. 2014 , 1311-1334	
1065	Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. 2014 , 2014, 342524	69
1064	Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 2014 , 19, 746-50	22
1063	Biomarker validation: common data analysis concerns. 2014 , 19, 886-91	18

1062	Asparagine synthetase expression and its potential prognostic value in patients with NK/T cell lymphoma. 2014 , 32, 853-9	11
1061	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. 2014 , 2014, 135-43	8
1060	Optimal disease surveillance strategies in non-Hodgkin lymphoma. 2014 , 2014, 481-7	11
1059	Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. 2014 , 55, 773-80	58
1058	Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma. 2014 , 55, 2384-6	2
1057	R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. 2014 , 99, 1343-9	64
1056	PET/CT zur Therapiekontrolle beim Hodgkin-Lymphom des Erwachsenen: Hängt die Indikation zur Strahlentherapie vom Ergebnis der PET/CT ab?. 2014 , 35, 97-102	
1055	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. 2014 , 99, 505-10	26
1054	Radiological monitoring of the treatment of solid tumors in practice. 2014 , 186, 466-73	8
1053	Radiological evaluation of the therapeutic response of malignant diseases: status quo, innovative developments and requirements for radiology. 2014 , 186, 927-36	4
1052	Therapy response evaluation of malignant lymphoma in a multicenter study: comparison of manual and semiautomatic measurements in CT. 2014 , 186, 768-79	
1051	Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. 2014 , 55, 2728-38	37
1050	Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. 2014 , 89, 363-8	57
1049	Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. 2014 , 165, 489-96	47
1048	Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome. 2014 , 89, 1011-3	4
1047	Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3736-43	2.2 223
1046	Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. 2014 , 55, 526-32	36
1045	Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. 2014 , 105, 840-6	42

1044	Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. 2014 , 55, 583-7	20
1043	Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. 2014 , 55, 1936-44	49
1042	Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. 2014 , 20, 5641-51	28
1041	Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. 2014 , 166, 140-2	27
1040	The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia. 2014 , 45, 2471-9	15
1039	Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. 2014 , 167, 327-36	31
1038	Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. 2014 , 120, 2122-9	25
1037	Synchronous diffuse large B-cell lymphoma and squamous cell lung carcinoma. 2014 , 2, 33-5	8
1036	Efficacy of ¹²⁵ I-anti-tumor necrosis factor-α antibody in relapsed/refractory extranodal marginal-zone lymphoma. 2014 , 32, 10-5	18
1035	Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease. 2014 , 55, 1281-7	8
1034	Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma. 2014 , 167, 141-4	5
1033	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. 2014 , 123, 2944-52	403
1032	A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. 2014 , 120, 1194-202	22
1031	Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone. 2014 , 32, 139-44	8
1030	Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. 2014 , 55, 1053-60	12
1029	R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma. 2014 , 93, 70-6	11
1028	A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type. 2014 , 55, 2955-7	8
1027	Peripheral blood CD4/CD19 cell ratio is an independent prognostic factor in classical Hodgkin lymphoma. 2014 , 55, 1596-601	3

1026	Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. 2014 , 93, 129-36	18
1025	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). 2014 , 25, 442-7	51
1024	Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma: a single institutional experience. 2014 , 166, 60-8	25
1023	Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study. 2014 , 27, 681-91	23
1022	Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. 2014 , 105, 1170-5	52
1021	Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome. 2014 , 55, 2048-55	25
1020	Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer. 2014 , 4, 12	14
1019	Imaging Biomarkers and Surrogate Endpoints in Oncology Clinical Trials. 2014 , 29-42	1
1018	[News in hodgkin lymphoma therapy]. 2014 , 101, 68-74	
1017	Does tumoral (111)In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing (90)Y-ibritumomab radioimmunotherapy?. 2014 , 24, 3191-8	3
1016	Whole-body DWI in patients with lymphoma: imaging findings, pitfalls, and limitations. 2014 , 14,	78
1015	A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival. 2014 , 15, 113	12
1014	Insight on automated lesion delineation methods for PET data. 2014 , 4, 69	16
1013	Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry. 2014 , 53, 927-34	25
1012	Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature. 2014 , 93, e121	46
1011	Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma. 2014 , 39, 772-6	13
1010	Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy. 2014 , 35, 908-15	11
1009	Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. 2014 , 38, 494-501	38

1008	High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma. 2014 , 65, 490-500		31
1007	Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. 2014 , 20, 6398-405		69
1006	Rare Lymphomas. 2014 ,		
1005	Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. 2014 , 99, 1738-45		19
1004	Musculoskeletal applications of PET/MR. 2014 , 18, 203-16		15
1003	Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival. 2014 , 100, 370-8		4
1002	Ocular adnexal lymphoma: validation of American Joint Committee on Cancer seventh edition staging guidelines. 2014 , 98, 1255-60		27
1001	Ocular adnexal follicular lymphoma: a multicenter international study. 2014 , 132, 851-8		53
1000	Clinical features and treatment outcomes of intravascular large B-cell lymphoma: a single-center experience in Korea. 2014 , 131, 18-27		13
999	Clinical features of testicular lymphoma. 2014 , 131, 187-92		0
998	Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP. 2014 , 131, 156-61		6
997	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. 2014 , 7, 44		59
996	Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3137-43	2.2	127
995	Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients. 2014 , 131, 193-9		18
994	Limited positron emission tomography-computed tomography for restaging of lymphoma: a strategy for reducing radiation exposure among patients with early-stage curable lymphoma. 2014 , 131, 239-44		3
993	Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. 2014 , 55, 2508-13		19
992	Comparison of the International Harmonization Project, London and Gallamini criteria in the interpretation of 18F-FDG PET/CT examinations after first-line treatment in Hodgkin's lymphoma. 2014 , 35, 169-75		5
991	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. 2014 , 25, 447-54		31

990	The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. 2014 , 38, 323-8	17
989	The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. 2014 , 50, 260-6	26
988	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. 2014 , 15, 69-77	441
987	Hematopoietic cell transplantation for mantle cell lymphoma: predictive value of pretransplant positron emission tomography/computed tomography and bone marrow evaluations for outcomes. 2014 , 14, 114-21	20
986	Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study. 2014 , 55, 533-7	14
985	[Oncological imaging for therapy response assessment]. 2014 , 54, 69-78; quiz 79-80	4
984	Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma. 2014 , 93, 995-1000	20
983	Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. 2014 , 41, 867-77	28
982	Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. 2014 , 32, 489-99	61
981	Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: comparison with CT in a prospective multicenter study. 2014 , 40, 26-36	42
980	Functional Imaging in Oncology. 2014 ,	1
979	Evaluation of significance of lymphocyte subpopulations and non-specific serologic markers in B-cell non-Hodgkin's lymphoma patients. 2014 , 20, 649-54	1
978	HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China. 2014 , 31, 845	11
977	The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients. 2014 , 31, 880	3
976	Assessment of the nature of residual masses at end of treatment in lymphoma patients using volume perfusion computed tomography. 2014 , 24, 770-9	5
975	Current role of FDG PET/CT in lymphoma. 2014 , 41, 1004-27	51
974	Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. 2014 , 93, 403-9	71
973	PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. 2014 , 41, 408-15	29

972	Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass. 2014 , 164, 694-700		32
971	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. 2014 , 166, 69-76		32
970	Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. <i>Journal of Clinical Oncology</i> , 2014 , 32, 798-808	2.2	341
969	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10'002. 2014 , 165, 102-11		68
968	PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma. 2014 , 370, 1008-18		784
967	Hematopoietic tumors of the female genital system: imaging features with pathologic correlation. 2014 , 39, 922-34		4
966	Medical Imaging in Clinical Trials. 2014 ,		14
965	Role of PET in lymphoma. 2014 , 15, 248-61		29
964	How we manage follicular lymphoma. 2014 , 28, 1388-95		71
963	Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma. 2014 , 93, 469-75		5
962	Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. 2014 , 20, 253-64		97
961	Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. <i>Journal of Clinical Oncology</i> , 2014 , 32, 44-50	2.2	165
960	PI3-kinase inhibitors in chronic lymphocytic leukemia. 2014 , 9, 33-43		21
959	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. 2014 , 15, 48-58		372
958	Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone. 2014 , 28, 49-63		15
957	FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?. 2014 , 28, 87-103		8
956	Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?. 2014 , 55, 2484-9		22
955	Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma. 2014 , 55, 2196-8		3

954	Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. 2014 , 55, 1591-7	47
953	The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement. 2014 , 89, 865-7	6
952	'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. 2014 , 166, 369-74	39
951	Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. 2014 , 164, 258-65	54
950	Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. 2014 , 164, 659-67	19
949	Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. 2014 , 89, 726-31	57
948	Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients. 2014 , 14, 474-9	17
947	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. 2014 , 38, 1446-50	13
946	Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures. 2014 , 272, 262-74	34
945	Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study. 2014 , 39, 619-28	12
944	Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients. 2014 , 166, 306-8	10
943	Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. 2014 , 74, 637-46	16
942	Interim and end-treatment positron emission tomography scan in aggressive B-cell lymphoma: we still lack an interpretation key. 2014 , 55, 1447-8	1
941	Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. 2014 , 92, 204-10	45
940	Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma. 2014 , 41, 2023-30	8
939	Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7. 2014 , 38, 1320-6	3
938	The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma. 2014 , 38, 1291-8	5
937	PET-CT restaging: a surrogate for follicular lymphoma?. 2014 , 1, e2-3	1

936	Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. 2014 , 1, e17-27		108
935	Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy. 2014 , 55, 1047-53		36
934	Rituximab-including combined modality treatment for primary thyroid lymphoma: an effective regimen for elderly patients. 2014 , 24, 994-9		10
933	Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma. 2014 , 55, 216-22		25
932	Influence of ex vivo purging with CliniMACS CD34(+) selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma. 2014 , 164, 555-64		6
931	British HIV Association guidelines for HIV-associated malignancies 2014. 2014 , 15 Suppl 2, 1-92		40
930	False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 51-6	2.2	21
929	Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. 2014 , 55, 569-73		68
928	Evolving treatment paradigms for primary mediastinal diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1751-3	2.2	5
927	Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3059-68	2.2	2407
926	[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1769-75	2.2	120
925	Double hit lymphoma: the MD Anderson Cancer Center clinical experience. 2014 , 166, 891-901		244
924	Guidelines for the first line management of classical Hodgkin lymphoma. 2014 , 166, 34-49		52
923	Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients. 2014 , 89, 1047-1052		29
922	A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. 2014 , 154, 37-46		22
921	How to manage mantle cell lymphoma. 2014 , 28, 2117-30		39
920	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. 2014 , 15, 1019-26		215
919	In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2705-11	2.2	67

918	Critères de la réponse tumorale en imagerie : RECIST, mRECIST, Cheson. 2014 , 95, 678-692		
917	Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. 2014 , 15, 966-74		259
916	Precision therapy for lymphoma--current state and future directions. 2014 , 11, 585-96		55
915	Primary mediastinal large B-cell lymphoma. 2014 , 9, 273-83		23
914	Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy. 2014 , 31, 185		8
913	Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3497-505	2.2	175
912	Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma. 2014 , 9, 443-55, vi		3
911	A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. 2014 , 25, 2398-2404		10
910	Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy. 2014 , 39, 1394-400		11
909	Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era. 2014 , 100, 386-92		12
908	The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab. 2014 , 93, 1755-64		21
907	CD19 as a molecular target in CNS autoimmunity. 2014 , 128, 177-90		16
906	Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3048-58	2.2	927
905	Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma. 2014 , 20, 1804-12		17
904	Utility of quantitative FDG-PET/CT for the detection of bone marrow involvement in follicular lymphoma: a histopathological correlation study. 2014 , 43, 1231-6		12
903	Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. 2014 , 41, 1735-43		105
902	Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. 2014 , 93, 617-26		39
901	Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. 2014 , 93, 1305-12		51

900	Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis. 2014 , 93, 1287-95	27
899	The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. 2014 , 93, 1297-304	45
898	Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. 2014 , 93, 1345-51	8
897	A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma. 2014 , 93, 1637-44	10
896	ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. 2014 , 93, 1745-53	25
895	Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. 2014 , 93, 1853-7	11
894	Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. 2014 , 93, 1867-77	11
893	Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. 2014 , 93, 1879-87	40
892	Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. 2014 , 93, 1889-94	38
891	Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. 2014 , 32, 1213-25	18
890	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. 2014 , 7, 24	119
889	A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). 2014 , 123, 3398-405	206
888	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 2014 , 27, 958-71	99
887	Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. 2014 , 20, 1864-8	49
886	Which Hodgkin's patients in the Unites States should be treated with BEACOPP?. 2014 , 9, 222-6	1
885	Managing HIV and Hodgkin lymphoma in the twenty-first century. 2014 , 9, 227-32	5
884	Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. 2014 , 31, 56	10
883	Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. 2014 , 31, 902	27

882	Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. 2014 , 99, 737-42	23
881	Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy. 2014 , 100, 88-95	15
880	Prognostic Value of Metabolic Tumor Volume Estimated by (18) F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease. 2014 , 48, 187-95	32
879	CD30 as a therapeutic target for lymphoma. 2014 , 28, 181-209	23
878	R-CHOP versus R-COMP: are they really equally effective?. 2014 , 26, 648-52	11
877	Limited-stage hodgkin lymphoma: managing uncertainty. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1180-2	7
876	A phase I study of the first-in-class antimetochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. 2014 , 20, 5255-64	60
875	Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. 2014 , 166, 77-83	35
874	Response evaluation and monitoring of multiple myeloma. 2014 , 7, 33-42	7
873	When should FDG-PET be used in the modern management of lymphoma?. 2014 , 164, 315-28	44
872	Refinement of the definition of permissible HLA-DPB1 mismatches with predicted indirectly recognizable HLA-DPB1 epitopes. 2014 , 20, 1705-10	26
871	Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. 2014 , 166, 920-8	11
870	Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy. 2014 , 14, 37-42	28
869	Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma. 2014 , 33, 148-52	2
868	Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. 2014 , 38, 34-41	23
867	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. 2014 , 25, 1404-1410	114
866	Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. 2014 , 32, 187-91	34
865	Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. 2014 , 14, 50-5	27

864	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. 2014 , 15, 730-7		135
863	Prognostic evaluation of PET/CT in residual post-chemotherapy masses in patients with diffuse large B-cell lymphoma and its impact on survival. 2014 , 45, 921-928		1
862	Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis. 2014 , 20, 1198-203		16
861	Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma. 2014 , 14, 277-83		16
860	Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma. 2014 , 42, 39-45		11
859	High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving		15
858	Standardized uptake value for 18F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with Diffuse Large B-Cell Lymphoma. 2014 , 33, 148-152		
857	Towards integrating positron emission tomography for work-up of patients with Sjögren's syndrome and associated lymphomas. 2014 , 13, 327-9		9
856	PET/CT in initial staging and therapy response assessment of early mediastinal lymphoma. 2014 , 45, 61-67		2
855	Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. 2014 , 20, 885-90		37
854	Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. 2014 , 25, 296-302		25
853	Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. 2014 , 55, 2328-34		40
852	18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. 2014 , 55, 811-6		17
851	Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients?. 2014 , 93, 340-8		23
850	Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1776-81	2.2	48
849	Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity--a preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging. 2014 , 83, 1655-64		27
848	Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. 2014 , 89, 384-91		6
847	Primary non-Hodgkin lymphoma of the ovary. 2014 , 41, e19-30		7

846	A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. 2014 , 20, 213-20	96
845	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. 2014 , 123, 1214-7	404
844	Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. 2014 , 95, 689-703	37
843	Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. 2014 , 20, 1444-7	18
842	Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. 2014 , 25, 577-82	7
841	TEP infimaire dans les lymphomes. 2014 , 38, 184-187	2
840	Prognostic factors and treatment efficacy in patients with primary diffuse large B-cell lymphoma of the bone: single institute experience over 11 years. 2014 , 53, 95-101	12
839	18 F-FDG PET/CT imaging for a gastrointestinal mantle cell lymphoma with multiple lymphomatous polyposis. 2014 , 20, 5141-6	6
838	Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. 2014 , 99, 346-52	114
837	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. 2014 , 99, e126	7
836	Midtreatment evaluation of lymphoma response to chemotherapy by volume perfusion computed tomography. 2014 , 38, 123-30	6
835	Neurolymphomatosis in a patient with extranodal NK/T-cell lymphoma, nasal-type: a case report and literature review. 2014 , 53, 471-5	9
834	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. 2014 , 124, 3553-60	44
833	Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. 2014 , 124, 3029-31	32
832	Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). 2014 , 123, 1665-73	52
831	Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- β as therapy for previously treated indolent non-Hodgkin lymphoma. 2014 , 123, 3406-13	173
830	Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. 2014 , 123, 3567-73	63
829	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. 2014 , 123, 2953-9	77

828	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. 2014 , 123, 3095-100	224
827	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. 2014 , 124, 2190-5	88
826	A prospective study of mediastinal gray-zone lymphoma. 2014 , 124, 1563-9	70
825	Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. 2014 , 124, 1259-65	29
824	Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. 2014 , 124, 1570-7	208
823	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. 2014 , 124, 3356-64	30
822	BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. 2014 , 124, 2306-12	30
821	Hodgkin's lymphoma. 2014 , 497-515	
820	Ibritumomab tiuxetan plus BEAM in refractory diffuse large B-cell lymphoma. 2014 , 99, e108	
819	Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis. 2014 , 99, e41-3	26
818	Segmental "misty mesentery" on FDG PET/CT: an uncommon manifestation of mesenteric lymphoma. 2014 , 39, 84-6	3
817	Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphoma. 2015 , 10, 2925-2930	5
816	HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. 2015 , 29, 811-8	23
815	Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma. 2015 , 27, 99-105	9
814	Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. 2015 , 90, 230-4	8
813	Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review. 2015 , 4, 1817-27	2
812	A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma. 2015 , 170, 886-90	25
811	Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma. 2015 , 171, 662-5	1

810	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. 2015 , 125, 658-67	79
809	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. 2015 , 125, 82-9	37
808	How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. 2015 , 125, 1226-35; quiz 1355	37
807	Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. 2015 , 125, 1236-43	176
806	A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. 2015 , 125, 242-8	103
805	Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. 2015 , 125, 1394-402	185
804	FDG PET-CT in follicular lymphoma: a case-based evidence review. 2015 , 125, 1078-82	14
803	The efficacy of ibrutinib in the treatment of Richter syndrome. 2015 , 125, 1676-8	57
802	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. 2015 , 126, 950-6	111
801	Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. 2015 , 126, 36-41	33
800	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. 2015 , 126, 842-50	111
799	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. 2015 , 125, 3024-31	212
798	Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. 2015 , 126, 1893-901	87
797	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. 2015 , 126, 739-45	268
796	Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. 2015 , 126, 2798-804	97
795	Radiotherapy for advanced-stage aggressive non-Hodgkin lymphoma. 2015 ,	
794	Hodgkin lymphoma, version 2.2015. 2015 , 13, 554-86	26
793	Bone marrow uptake of indolent non-Hodgkin lymphoma on PET/CT with histopathological correlation. 2015 , 36, 1035-41	4

792	Tetrasomy X in a Child with Upper Limb Deformity. 2015 , 52, 439	1
791	FDG-PET scan in lymphoma: silver anniversary. 2015 , 3, 251-252	1
790	Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy. 2015 , 6, 470-8	22
789	Chł̄niak rozlany z duŹych limfocytów B âłczy R-CHOP-21 jest leczeniem optymalnym?. 2015 , 46, 100-106	
788	Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. 2015 , 8, 70	20
787	Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. 2015 , 8, 80	5
786	Qualitative visual trichotomous assessment improves the value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in predicting the prognosis of diffuse large B-cell lymphoma. 2015 , 34, 264-71	2
785	Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. 2015 , 90, 778-83	53
784	The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. 2015 , 169, 701-10	23
783	A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. 2015 , 170, 679-86	18
782	Ambulatory Medical Assistance--After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy. 2015 , 15, 781	17
781	Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma. 2015 , 34, 608-13	9
780	Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study. 2015 , 95, 160-7	17
779	Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. 2015 , 29, 903-10	23
778	Follicular Lymphoma in a Patient with Previously Treated Early Breast Cancer; the Role of PET Imaging and Repeat Tissue Diagnosis. 2015 , 21, 691-2	
777	Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. 2015 , 171, 463-70	60
776	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. 2015 , 171, 788-97	10
775	The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients. 2015 , 170, 175-8	5

774	Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. 2015 , 171, 509-16	13
773	Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression. 2015 , 96, 232-9	4
772	ACR Appropriateness Criteria [®] Diffuse Large B-Cell Lymphoma. 2015 , 38, 610-20	5
771	The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma. 2015 , 40, 767-73	20
770	Autologous Transplant in Lymphoma: Experience in a Limited Resource Mexican Reference Center. 2015 , 06,	
769	Red blood cell distribution width as a simple negative prognostic factor in patients with diffuse large B-cell lymphoma: a retrospective study. 2015 , 56, 334-43	37
768	Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma. 2015 , 50, 97-102	2
767	The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. 2015 , 6, 87-92	2
766	Enhanced International Prognostic Index (NCCN-IPI), Charlson Comorbidity Index and absolute lymphocyte count as predictors for survival of elderly patients with diffuse large B cell lymphoma treated by immunochemotherapy. 2015 , 62, 988-95	11
765	Monitoring Reader Metrics in Blinded Independent Central Review of Oncology Studies. 2015 , 05,	
764	Real Benefit of Anthracycline-Based Chemotherapy in Elderly and Impaired Patients: a Retrospective Analysis. 2015 , 04,	
763	Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma. 2015 , 6, 45-53	7
762	The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. 2015 , 10, e0126615	16
761	Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy. 2015 , 10, e0127589	33
760	Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy. 2015 , 10, e0129064	8
759	The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. 2015 , 10, e0138341	12
758	Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma. 2015 , 10, e0140830	65
757	Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphoma. 2015 , 2015, 606752	2

756	Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations. 2015 , 29, 417-22	20
755	Imaging the posterior mediastinum: a multimodality approach. 2015 , 21, 293-306	16
754	Staging of Primary Abdominal Lymphomas: Comparison of Whole-Body MRI with Diffusion-Weighted Imaging and (18)F-FDG-PET/CT. 2015 , 2015, 104794	10
753	Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa. 2015 , 2015, 895105	19
752	Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma. 2015 , 21, 824-832	3
751	Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation. 2015 , 50, 160-6	2
750	Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)â 2015 , 26, 873-879	89
749	The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study. 2015 , 56, 2585-91	9
748	Rethinking clinical response and outcome assessment in a biologic age. 2015 , 17, 27	2
747	Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study. 2015 , 133, 165-73	41
746	Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. 2015 , 4, e990773	20
745	Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. 2015 , 15, 335-40	6
744	Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience. 2015 , 90, E103-10	21
743	A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. 2015 , 125, 4024-31	198
742	High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study. 2015 , 102, 181-7	25
741	Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies. 2015 , 133, 141-50	15
740	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. 2015 , 56, 2569-78	26
739	Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. 2015 , 21, 1605-11	28

738	Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP. 2015 , 68, 733-8		12
737	Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma. 2015 , 56, 927-35		27
736	Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry. 2015 , 33, 120-8		12
735	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2492-9	2.2	291
734	Outcomes of Treatment in Slovene Follicular Lymphoma Patients. 2015 , 15, 586-91		1
733	Utility of F-18 FDG PET/CT on the evaluation of primary bone lymphoma. 2015 , 84, 2275-9		16
732	Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas. 2015 , 45, 914-20		
731	Incidentally discovered diffuse large B-cell lymphoma limited to the endocervical mucosa in a young female patient. 2015 , 80, 134-8		1
730	The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma. 2015 , 56, 676-81		5
729	Outcomes and endpoints in cancer trials: bridging the divide. 2015 , 16, e43-52		56
728	A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. 2015 , 168, 811-9		131
727	Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients. 2015 , 56, 293-300		7
726	CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. 2015 , 56, 332-41		24
725	Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. 2015 , 56, 1750-5		20
724	(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. 2015 , 56, 2005-12		20
723	Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas. 2015 , 32, 353		5
722	Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. 2015 , 56, 2032-8		33
721	Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era. 2015 , 39, 211-5		6

720	Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy. 2015 , 39, 198-203		8
719	Manifestaciones otorrinolaringológicas de las hemopatías del adulto. 2015 , 44, 1-15		
718	Prognostic significance of the number and type of extra nodal localizations of DLBCL in the rituximab era. 2015 , 46, 49-55		
717	Management of diffuse large B-cell lymphoma (DLBCL). 2015 , 165, 271-88		45
716	FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. 2015 , 21, 1525-9		104
715	Prognostic value of tumor necrosis at CT in diffuse large B-cell lymphoma. 2015 , 84, 372-377		23
714	The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60 years of age. 2015 , 33, 133-40		13
713	Comparison of 18F-labelled fluoro-2-deoxyglucose-PET with conventional computed tomography for staging and response assessment in paediatric and adult patients with nodular lymphocyte-predominant Hodgkin's lymphoma. 2021 , 42, 899-906		
712	F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study. 2021 , 48, 2883-2893		5
711	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1129-1138	2.2	7
710	Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation. 2021 , 38, 3489-3505		0
709	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). 2021 , 96, 834-845		0
708	Current and future best practice in imaging, staging, and response assessment for Non-Hodgkin's lymphomas: the Specialist Integrated Haematological Malignancy Imaging Reporting (SIHMIR) paradigm shift. 2021 , 76, 391.e1-391.e18		1
707	A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan. 2021 , 11, 10069		2
706	Outcome of Diffuse Large B-Cell Lymphoma with First-line Chemotherapy. 2021 , 5, 03-09		
705	Adding value to tumor staging in head and neck cancer: The role of metabolic parameters as prognostic factors. 2021 , 43, 2477-2487		1
704	A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study). 2021 , 193, 1123-1133		3
703	Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. 2021 , 40, 3989-4003		7

702	Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience. 2021 , 100, 1837-1847	1
701	Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. 2021 , 112, 2426-2435	7
700	Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study. 2021 , 134, 1299-1309	2
699	Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1. 2021 , 38, 3266-3280	3
698	Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome after High-Dose Chemotherapy. 2021 , 13,	0
697	Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study. 2021 , 193, 906-914	1
696	Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies. 2021 , 21, e432-e448	6
695	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. 2021 , 10, 5101-5109	1
694	Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. 2021 , 11, 687374	2
693	Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement. 2021 , 13,	
692	Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the Phase III MabCute study. 2021 ,	0
691	Imaging Assessment of Tumor Response in the Era of Immunotherapy. 2021 , 11,	1
690	Dismal outcome of relapsed or primary refractory adult T-cell lymphoblastic lymphoma: A retrospective study from China. 2021 ,	
689	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy. 2021 , 9,	3
688	The Clinical and Biological Effects of PD-1 Expression on Tumor Cells in Diffuse Large B-Cell Lymphoma. 2021 , 2, 368-381	0
687	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. 2021 , 26, 597-609	5
686	Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. 2021 , 27, 4690-4695	4
685	Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study. 2021 , 39, 498-505	0

684	Is It Time to Call Time on Bone Marrow Biopsy for Staging Ewing Sarcoma (ES)?. 2021 , 13,	1
683	Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. 2021 , 9,	2
682	Older patients (aged ≥80 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. 2021 ,	3
681	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. 2021 , 127, 3390-3402	5
680	A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China. 2021 , 134, 1584-1592	0
679	A mass transfer model for computational prediction of proliferation and therapy outcome of non-Hodgkin lymphoma. 2021 , 125, 105332	2
678	Efficacy of siltuximab in the treatment of idiopathic multicentric castlemans disease, the first Polish, real-world experience with long-term observation. 2021 , 62, 3031-3034	1
677	Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer. 2021 , 12, 647733	2
676	A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies. 2021 , 21, 823-830	0
675	Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. 2021 , 112, 3627-3635	6
674	Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience. 2021 , 21, e946-e959	1
673	Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. 2021 , 111, 1145-1154	4
672	Imaging biomarkers for evaluating tumor response: RECIST and beyond. 2021 , 9, 52	10
671	Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update. 2021 , 127, 3727-3741	2
670	Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. 2021 ,	2
669	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. 2021 , 5, 2852-2862	5
668	Clinical impact of comprehensive geriatric assessment in patients aged 80 years and older with diffuse large B-cell lymphoma receiving rituximab-mini-CHOP: a single-institute retrospective study. 2021 , 1	0
667	Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis. 2021 , 163, 103377	1

666	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. 2021 , 194, 690-700	12
665	Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma. 2021 , 53, 837-846	5
664	A picture is worth a thousand words: a history of diagnostic imaging for lymphoma. 2021 , 94, 20210285	0
663	Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma. 2021 , 1	1
662	Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center. 2021 , 27, 1609867	0
661	Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma. 2021 , 9, 1178	0
660	Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. 2021 , 1-13	0
659	A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma. 2021 , 14, 101085	8
658	CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. 2021 , 9, 1061-1070	8
657	Correlation between alterations in blood flow of malignant lymphomas after induction chemotherapies and clinical outcomes: a pilot study utilising contrast-enhanced ultrasonography for early interim evaluation of lymphoma treatment. 2021 , 76, 550.e9-550.e17	0
656	Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development. 2021 , 106, 106434	3
655	Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. 2021 , 106, 2417-2426	20
654	Significance of initial, interim and end-of-therapy F-FDG PET/CT for predicting transformation risk in follicular lymphoma. 2021 , 21, 394	0
653	The Role of Interim PET/CT on Survival in Diffuse Large B Cell Lymphoma. 2021 , 21, e922-e927	1
652	Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review. 2021 , 13,	0
651	Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. 2021 , 11, 147	0
650	Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100105	2.2 6
649	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. 2021 ,	2

648	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. 2021 , 5, 3445-3456	2
647	Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma. 2021 , 14, 867-875	1
646	Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy. 2021 , 21, 941-956	
645	Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy. 2021 , 1-4	
644	Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals. 2021 , 1-9	0
643	Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. 2021 , 27, 911.e1-911.e7	1
642	Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma. 2021 , 11, 713577	0
641	A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. 2021 , 1-7	2
640	New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT. 2021 , 13,	2
639	RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. 2021 , 27, 6124-6134	7
638	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. 2021 , 5, 3647-3655	0
637	Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL. 2021 , 5, 4198-4210	1
636	Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. 2021 , 6, 100172	0
635	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. 2021 , 8, e562-e571	4
634	Long-term efficacy and safety of chemotherapy-free first-line iodine-131-rituximab radioimmunotherapy of follicular lymphoma. 2021 ,	0
633	Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma. 2021 , 1	
632	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. 2021 , 1-8	1
631	Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. 2021 , 195, 201-209	5

630	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. 2021 , 1-9	0
629	Improved Progression-Free Survival for Bulky and Non-Bulky Advanced Stage Diffuse Large B-Cell Lymphoma With Consolidative Radiation Therapy: A Bi-Institutional Analysis. 2021 , 13, e17107	0
628	Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. 2021 , 5, 3862-3872	3
627	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. 2021 , 27, 5847-5856	0
626	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. 2021 , 5, 4149-4155	10
625	Experience of Nivolumab Prior to Autologous Stem Cell Transplant for Relapsed Refractory Hodgkin Lymphoma. 1	
624	Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. 2021 , 5, 3387-3396	4
623	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. 2021 , 5, 3528-3539	6
622	Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission. 2021 ,	9
621	Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience. 2021 , 21, 498	1
620	PET Imaging for Hematologic Malignancies. 2021 , 59, 705-723	2
619	Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma. 2021 , 1	1
618	The mTOR Inhibitor Temozolomide Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatin (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial. 2021 , 5, e636	0
617	Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. 2021 , 14, 140	4
616	Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. 2021 , 13,	5
615	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. 2021 , 5, 3354-3361	3
614	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. 2021 ,	2
613	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. 2021 , 11, 160	0

612	In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [F]FDG and [Cu]Cu-LLP2A PET. 2021 , 11, 97	0
611	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. 2021 , 9, CD013365	2
610	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. 2021 , 13,	2
609	Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. 2021 , 5, 4674-4685	2
608	Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis. 2021 , 36, 1181-1189	1
607	Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation. 2021 , 26, e933365	
606	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. 2021 , 195, 757-763	2
605	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. 2021 ,	10
604	Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases. 2021 , 10781552211038001	0
603	Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study.. 2021 , 135, 433-440	1
602	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. 2021 , 5, 4504-4514	1
601	Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. 2021 , 1	2
600	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. 2021 , 27, 863.e1-863.e5	1
599	BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas. 2021 , 110, 106689	1
598	FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. 2021 , 51, 554-571	2
597	Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. 2021 , 157, 132-139	1
596	The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era. 2021 , 110, 106715	1
595	R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with rearrangement or double expression of and. 2021 , 12, 2059-2064	0

594	The presence of a bulky mediastinal mass of 7 cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT. 2021 , 62, 1313-1324	4
593	Circulating long non-coding RNAs HOTAIR, Linc-p21, GAS5 and XIST expression profiles in diffuse large B-cell lymphoma: association with R-CHOP responsiveness. 2021 , 11, 2095	2
592	Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. 2021 , 10, 999-1011	10
591	Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. 2020 , 126, 2279-2287	6
590	Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. 2020 , 38, 244-256	8
589	Non-Hodgkin's Lymphoma. 2010 , 583-592	2
588	Orbital and Ocular Adnexal Lymphoma. 2015 , 145-153	1
587	HTLV-1-Associated T-cell Diseases. 2013 , 113-135	2
586	Cancer Imaging in Immunotherapy. 2020 , 1244, 309-324	2
585	Clinical Evaluation. 2015 , 95-106	1
584	Functional Imaging in Hodgkin Lymphoma. 2015 , 107-130	2
583	Background and Rationale for Radiotherapy in Early-Stage Hodgkin Lymphoma. 2011 , 7-20	0
582	Prognostic Factors. 2011 , 97-115	1
581	Multi-state Models Used in Oncology Trials. 2014 , 283-304	1
580	Head and Neck Tumors. 2016 , 441-480	2
579	Clinical Implications of the Role of 18FDG-PET/CT in Malignant Lymphomas. 2014 , 249-265	1
578	Non-Hodgkin's Lymphoma. 2008 , 2371-2404	3
577	Malignant Lymphomas and Lymphadenopathies. 2009 , 417-505	4

576	Non-Hodgkin Lymphoma. 2014 , 2033-2059.e8	1
575	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. 2020 , 26, 1099-1105	3
574	A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. 2017 , 17, 347-353	19
573	Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients. 2016 , 6, 28834	13
572	A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy. 2020 , 61, 2136-2144	3
571	Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study. 2020 , 99, e23412	2
570	Postchemotherapy Histiocyte-rich Pseudotumor Mimicking Residual Lymphoma: A Report of 11 Cases Correlating Clinicopathologic and Radiologic Findings. 2021 , 45, 160-168	4
569	Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases. 2018 , 21, 93-101	4
568	Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era. 2017 , 13, 226-233	0
567	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. 2020 , 189, 661-671	8
566	Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. 2020 , 189, e86-e90	11
565	Comparison of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma. 2019 , 5,	7
564	Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. 2019 , 129, 4451-4463	48
563	CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. 2011 , 121, 1822-6	709
562	Clinical responses with T lymphocytes targeting malignancy-associated light chains. 2016 , 126, 2588-96	207
561	Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. 2020 , 11, 2040620720902899	
560	How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. 2012 , 2012, 322-327	19
559	Interim PET-CT in the management of diffuse large B-cell lymphoma. 2012 , 2012, 397-401	24

558	Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells. 2020 , 135, 2425-2427	9
557	Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. 2020 , 4, 22	2
556	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. 2020 , 4, 63	18
555	Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience. 2019 , 24, 175-184	5
554	Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children. 2016 , 22, 4992-5002	8
553	Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients . 2016 , 22, 4297-4311	2
552	Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. 2012 , 7, e41658	106
551	Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival. 2014 , 9, e106745	16
550	Clinicopathological Analysis of Ocular Adnexal Extranodal Marginal Zone B-Cell Lymphoma with IgG4-Positive Cells. 2015 , 10, e0131458	10
549	Simultaneous [18F]FDG-PET/MRI: Correlation of Apparent Diffusion Coefficient (ADC) and Standardized Uptake Value (SUV) in Primary and Recurrent Cervical Cancer. 2015 , 10, e0141684	36
548	Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. 2016 , 11, e0162965	22
547	A purified, fermented, extract of <i>Triticum aestivum</i> has lymphomacidal activity mediated via natural killer cell activation. 2018 , 13, e0190860	4
546	Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma. 2010 , 128, 14-7	5
545	The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population. 2011 , 66, 919-22	6
544	Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China. 2020 , 25, e1202-e1208	4
543	Comparison of the Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Glasgow Prognostic Score in Diffuse Large B-Cell Lymphoma. 2016 , 17,	1
542	MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma. 2016 , 7, 53808-53819	17
541	Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma. 2016 , 7, 56574-56583	6

540	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. 2016 , 7, 67521-67531	36
539	Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. 2016 , 7, 72219-72228	4
538	Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. 2016 , 7, 83544-83553	33
537	A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy. 2017 , 8, 20362-20370	6
536	Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). 2017 , 8, 13367-13374	6
535	Intensity-modulated radiotherapy has superior outcomes to three-dimensional conformal radiotherapy in patients with stage IE-IIe extranodal nasal-type natural killer/T-cell lymphoma. 2017 , 8, 60504-60513	4
534	Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas. 2017 , 8, 33487-33500	15
533	A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. 2017 , 8, 47007-47019	14
532	Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma. 2017 , 8, 47790-47800	8
531	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. 2017 , 8, 91703-91710	12
530	Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas. 2017 , 8, 81329-81342	3
529	Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. 2017 , 8, 76231-76240	10
528	Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT. 2017 , 8, 85110-85119	1
527	Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients. 2017 , 8, 99104-99111	4
526	Clinical and histological features of primary testicular diffuse large B-cell lymphoma: a single center experience in China. 2017 , 8, 112384-112389	7
525	Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study. 2017 , 8, 68583-68590	8
524	Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies. 2017 , 8, 79864-79875	10
523	Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding. 2017 , 8, 72818-72834	12

522	Prognostic significance of total metabolic tumor volume on F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. 2017 , 8, 99587-99600	25
521	The prognostic significance of CD11bCX3CR1 monocytes in patients with newly diagnosed diffuse large B-cell lymphoma. 2017 , 8, 92289-92299	4
520	Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. 2017 , 8, 92312-92323	6
519	Indolent lymphoma with composite histology and simultaneous transformation at initial diagnosis exhibit clinical features similar to diffuse large B-cell lymphoma. 2018 , 9, 19613-19622	6
518	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. 2018 , 9, 23443-23450	8
517	Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. 2019 , 10, 3827-3830	2
516	Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP. 2019 , 10, 5403-5411	7
515	A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma. 2016 , 7, 18585-93	5
514	Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. 2016 , 7, 27676-88	51
513	Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial. 2017 , 79, 407-413	7
512	Extranodal involvement in young patients with diffuse large B-cell lymphoma: distribution, prognostic value and treatment options. 2017 , 29, 57-65	6
511	PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma. 2017 , 29, 66-74	9
510	High-dose Chemotherapy with Stem Cell Rescue Provided Durable Remission for Classical Hodgkin Lymphoma-type Post-transplant Lymphoproliferative Disorder after Unrelated Cord Blood Transplantation: A Case Report and Review of the Literature. 2017 , 56, 1873-1877	1
509	[Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma]. 2019 , 91, 41-51	2
508	Prognostic Value of Baseline Radiomic Features of F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma. 2020 , 11,	17
507	Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma. 2015 , 54, 241-6	3
506	Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma. 2014 , 20, 2751-9	17
505	Patterns of care and treatment outcomes for primary thyroid lymphoma: a single institution study. 2013 , 31, 177-84	16

504	Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience. 2017 , 35, 317-324	2
503	Association between Lactate Dehydrogenase Levels to the Response of Non-Hodgkin Lymphoma in Elderly Patients Who Treated with First-Line Chemotherapy in Sanglah General Hospital. 2019 , 7, 1984-1986	1
502	miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma. 2020 , 19, 3487-3494	3
501	Clinical significance of nuclear factor B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. 2014 , 29, 785-92	14
500	Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party. 2016 , 31, 1030-1041	12
499	Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review. 2015 , 30, 684-93	5
498	The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation. 2018 , 33, 1169-1181	3
497	Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system. 2020 , 35, 946-956	6
496	Superior clinical impact of FDG-PET compared to MRI for the follow-up of a patient with sacral lymphoma. 2009 , 49, 109-15	5
495	Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic abdominal and pelvic cancers: short-term local control, metabolic response, and toxicity. 2010 , 1, 16-23	7
494	Efficacy and safety of biosimilar rituximab (Zytux TM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. 2020 , 12, 8296	1
493	Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study. 2015 , 61, 88-91	6
492	Appropriateness criteria of FDG PET/CT in oncology. 2015 , 25, 88-101	26
491	Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade). 2017 , 38, 51-58	2
490	Quantitative Assessment of Radionuclide Uptake and Positron Emission Tomography-computed Tomography Image Contrast. 2016 , 15, 167-72	2
489	Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program. 2017 , 38, 508-515	4
488	Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India. 2018 , 147, 464-470	3
487	Diffuse large B-cell lymphoma: An institutional analysis. 2018 , 7, 200-202	11

486	Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement. 2013 , 45, 112-7	5
485	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. 2015 , 47, 173-81	8
484	Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. 2019 , 51, 1302-1312	3
483	Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma. 2019 , 51, 1479-1487	6
482	Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labelled Phase II Trial. 2020 , 52, 374-387	9
481	Absolute Lymphocyte/Monocyte Ratio at Diagnosis and Interim Positron-Emission Tomography Predict Survival in Classical Hodgkin Lymphoma. 2013 , 04, 452-459	2
480	Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE. 2016 , 33, 209-15	1
479	Two-stage design for phase II oncology trials with relaxed futility stopping. 2016 , 9, 93-98	3
478	Evaluation of cancer treatment in the abdomen: Trends and advances. 2013 , 5, 126-42	2
477	Immune checkpoint inhibitors in patients with pretreated Hodgkin's lymphoma: a Korean single-center, retrospective study. 2020 , 55, 85-90	2
476	18F-FDG PET/CT for identifying the potential causes and extent of secondary hemophagocytic lymphohistiocytosis. 2016 , 22, 471-5	24
475	Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation. 2011 , 155, 63-9	12
474	Prognostic factors in follicular lymphoma in the rituximab era: how to identify a high-risk patient?. 2011 , 155, 99-108	3
473	The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma. 2012 , 31, 348-53	3
472	Quantitative Imaging Assessment for Clinical Trials in Oncology. 2019 , 17, 1505-1511	3
471	Time-to-treatment of diffuse large B-cell lymphoma in São Paulo. 2014 , 69, 367-71	2
470	High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center. 2020 , 11, 57-68	3
469	Prognostic sub-grouping of diffuse large B-cell lymphomas into germinal centre and post germinal centre groups by immunohistochemistry after 6 cycles of chemotherapy. 2012 , 13, 1341-7	4

468	Comparison of WHO and RECIST criteria for evaluation of clinical response to chemotherapy in patients with advanced breast cancer. 2012 , 13, 3213-8	25
467	Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review. 2021 , 35, 3401-3406	1
466	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. 2021 ,	0
465	Allogeneic Transplant and CAR-T Therapy After Autologous Transplant Failure in DLBCL: A Noncomparative Cohort Analysis. 2021 ,	4
464	End of treatment FDG-PET in primary mediastinal B-cell lymphoma treated with R-chemotherapy: Prognostic indicator and implications for consolidation radiotherapy. 2021 ,	
463	Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era. 2021 ,	2
462	Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. 2021 , 39, 871-879	2
461	Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma. 2021 , 5, 5300-5311	0
460	A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. 2021 , 1	1
459	Imaging. 2008 , 283-308	
458	The role of hematopoietic stem cell transplantation in Hodgkin lymphoma. 2009 , 144, 399-414	
457	Recent advances in the treatment of B-cell lymphoma. 2009 , 1,	
456	Lymphoma. 2010 , 513-554	
455	Monoclonal Antibody Therapy for Hematologic Malignancies. 2010 , 493-536	
454	Non-Hodgkinâs Lymphoma: Allogeneic Reduced Intensity Conditioning. 2010 , 109-125	
453	[Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long-term follow-up results]. 2009 , 150, 2133-8	
452	Lymphoma: Diagnostic and Therapeutic Applications of Radiopharmaceuticals. 2010 , 199-203	
451	A Case of Nodal Malignant Lymphoma in the Regional Lymph Node at Operation for Esophageal and Laryngeal Cancer. 2010 , 43, 33-37	

450 Gastrointestinal Lymphomas. **2010**, 445-460.e5

449 Non-Hodgkin's Lymphomas. **2010**, 1371-1379

448 Localisation gastro-intestinale. **2010**, 75-79

447 Imaging as a Localized Biomarker: Opportunities and Challenges. 1

446 Hodgkin Lymphoma in Special Populations and Rare Localizations. **2011**, 167-182

445 Background and Rationale for Radiotherapy in Advanced-Stage Hodgkin Lymphoma. **2011**, 21-29

444 Functional Imaging. **2011**, 77-95

443 The Management of HIV-Hodgkin Lymphoma. **2011**, 249-258

442 Evaluation of Response After Radiotherapy for Hodgkin Lymphoma. **2011**, 161-166

441 Clinical Evaluation. **2011**, 65-76

440 Overview of the Lymphoid Neoplasms. **2012**, 3-39

439 Hodgkin Lymphoma. 639-654

438 Non-Hodgkin Lymphoma. 655-685

437 FDG-PET Imaging in Haematological Patients with Pulmonary Infiltrates. **2011**, 235-242

436 Bone marrow. **2011**, 1927-2012

435 Lymphomes des sujets âgés ni sur-traiter ni sous-traiter, s'adapter. **2011**, 103-108

434 Lymphoproliferation and Lymphoma in Sjögren's Syndrome. **2011**, 345-355

433 Lymphoma: Differential Diagnosis of Mediastinal Masses and Response. **2011**, 193-198

- 432 Association of CD57+ Natural Killer Cells with Better Overall Survival in DLBCL Patients. **2011**, 45, 361 ○
- 431 Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity.
- 430 A case of an abdominal mass: follicular lymphoma. **2011**, 15, 61-4
- 429 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61
- 428 Pediatric Hodgkin's Lymphoma. **2012**, 1489-1503
- 427 Non-Hodgkin's Lymphoma. **2012**, 1545-1572
- 426 Lymphomas. **2013**, 153-187
- 425 Hodgkin Lymphoma. **2013**, 225-239
- 424 Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies. **2013**, 161-175
- 423 Lymphoma Surveillance Counterpoint: Japan. **2013**, 467-468
- 422 Future Directions in Aggressive Lymphomas. **2013**, 173-189
- 421 A case of primary malignant lymphoma of the lung with pleural dissemination. **2013**, 27, 170-174
- 420 Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimusutine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy. **2013**, 04, 448-451
- 419 Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma. **2013**, 04, 1298-1305
- 418 Diffuse Large B-Cell Lymphoma. **2013**, 177-202
- 417 Lymphoma: streamlining follow ups. **2013**, 35, 162
- 416 PATHOLOGIE TumorALE DU PARENCHYME PULMONAIRE. **2013**, 277-451
- 415 Imaging Criteria for Tumor Treatment Response Evaluation. **2014**, 13-25

- 414 Introduction to Lymphomas. **2014**, 235-238 0
- 413 Lymphomas: The Role of CT and MRI in Staging and Restaging. **2014**, 239-247 0
- 412 Functional Imaging in Clinical Use for the Assessment of Lymph Nodes in Oncological Patients. **2014**, 1271-1309
- 411 Monitoring Responses to Therapy in Oncology. **2014**, 155-171
- 410 Imaging Review Charters and Operational Considerations. **2014**, 65-82
- 409 Clinical Significance of Clonal Rearrangement of the Immunoglobulin Gene in the Bone Marrow of Patients with B-cell Non-Hodgkin Lymphoma. **2014**, 4, 125 1
- 408 Pediatric Molecular Imaging. **2014**, 571-595
- 407 Adult T-Cell Leukemia-Lymphoma. **2014**, 2076-2092.e4
- 406 Imaging. **2014**, 253-281.e3
- 405 Clinical features and treatment outcomes of patients with Hodgkin lymphoma: A single-center study of 36 cases. **2014**, 17, 15-24
- 404 Lymphomas and Lymphoproliferative Disorders. **2014**, 479-496
- 403 Lymphomes : principes th apeutiques et imagerie post-th apeutique. **2014**, 265-298
- 402 Adult Burkitt Lymphoma and Leukemia. **2014**, 171-194
- 401 Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading. **2014**, 2014, 3
- 400 The Challenge of Treating Elderly Patients with Mantle Cell Lymphoma. **2015**, 143-168
- 399 Treatment of Early Favorable Hodgkin Lymphoma. **2015**, 201-220
- 398 The Management of HIV-Hodgkin Lymphoma. **2015**, 307-318
- 397 Prognostic Factors. **2015**, 131-155 1

396 Role of radiation therapy for Hodgkin lymphoma. **2015**, 4, 17

395 Post-therapy Surveillance of Bone Tumors. **2015**, 211-219

394 Evaluation of Response in Malignant Tumors Treated with Targeted Agents. **2015**, 43-55

393 Managing advanced stage Hodgkin lymphoma. **2015**, 61, 75-6

392 FDG PET/CT in the Imaging of Mediastinal Masses. **2015**, 202-208

391 Onkologische Bildgebung zur Beurteilung des Therapieansprechens. **2015**, 91-100

390 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

389 Peripheral T-cell lymphomas. 187-200

388 Lymphoma. 392-414

387 Lymphoma. **2016**, 239-254

386 PET Scan Reporting in Clinical Practice. **2016**, 117-136

385 Diagnostic Applications of Nuclear Medicine: Lymphomas. **2016**, 1-42

384 [Therapy for primary mediastinal large B-cell lymphoma in accordance with the R-DA-EPOCH-21 program: The first results]. **2016**, 88, 37-42 3

383 Hodgkin Lymphoma in Children. **2016**, 295-304

382 PET/CT in RT Planning. **2016**, 99-115

381 [Follicular lymphoma. High-dose immunochemotherapy with autologous blood stem cell transplantation: Results of the first prospective study in Russia]. **2016**, 88, 62-71 1

380 18F-FDG PET/CT Imaging in Detection of Intravascular Large B-Cell Lymphoma. **2016**, 5, 10-11

379 PET Response-Adapted Treatment in Hodgkin Lymphoma. **2016**, 31-64

378 PET Scan for HL Restaging. **2016**, 15-30

377 Role of 18F-fl uorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Evaluation and Management of Lymphoma. **2016**, 14-23

376 Role of PET/CT in Pediatric Malignancy. **2017**, 537-575

375 Role of Positron-Emission Tomography in Prognosis of Outcomes of High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Hodgkinâs Lymphoma. **2016**, 9, 406-412

374 Primary Orbital Follicular Lymphoma: A Case Report and Review. **2017**, 11, XD01-XD03

1

373 Radiological Imaging in Lymphoma. **2017**, 25-31

372 Diagnostic Applications of Nuclear Medicine: Lymphomas. **2017**, 353-393

371 Soft Tissue Lymphoma. **2017**, 577-592

370 Clinical applications of PET/CT and SPECT/CT imaging. **2017**, 439-472

369 Lymphoma. 392-414

368 Blood biomarkers in adults with lymph node enlargement contribute to diagnostic significance of malignancy. **2017**, 8, 98533-98541

0

367 Resistance and Heterogeneity of Intratumoral Antibody Distribution. **2018**, 99-104

366 Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. **2018**, 8, 41

365 Conventional and Conformal Radiotherapy with and without Beam Intensity Modulation in Patients with Stage II Hodgkinâs Lymphoma with Supradiaphragmal Lesions. **2018**, 11, 70-77

364 PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkinâs Lymphoma. **2018**, 11, 213-219

2

363 Adult Burkitt lymphoma: An institutional experience with a uniform chemotherapy protocol. **2018**, 7, 195-199

0

362 Extranodal Localization of Aggressive Lymphoma. **2019**, 201-212

361 Clinical and Hematological Predictors of Response to First-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma. **2018**, 12, 68-72

1

- 360 Role of Modern Imaging with FDG-PET/CT in Aggressive Lymphoma. **2019**, 285-295
- 359 Hybrid Imaging and Radionuclide Therapy in Hemato-oncology. **2019**, 655-705
- 358 The Lower Peripheral Blood Lymphocyte to Monocyte Ratio Following Completion of First Line Chemotherapy Is a Risk Factor for Predicting Relapse in Patients with Diffuse Large B-Cell Lymphoma. **2019**, 10, 53-68
- 357 Quintessential Role of 18Fluorine Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Differentiation of Viable Tumor Tissue and Nondisease Desmoplastic Residue. **2019**, 34, 129-133
- 356 Development of methods to evaluate probability of reviewerâs assessment bias in blinded independent central review (BICR) imaging studies. **2019**,
- 355 Agresif B hreli Hodgkin dve Hodgkin lenfomada ilk basamak tedavi yannn FDG-PET/BT ile derlendirilmesinde rezidl SUVmax.
- 354 Primary Bone Lymphomas: Long-Term Results of a Prospective Single-Center Trial. **2019**, 12, 247-262 2
- 353 APPLICATION OF POSITRON EMISSION TOMOGRAPHY / COMPUTER TOMOGRAPHY FOR EVALUATING THE RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA / LYMPHOBLASTIC LYMPHOMA. **2019**, 64, 138-149
- 352 Evolution of Response Criteria in Immunotherapy. **2020**, 7-11
- 351 Clinical Features of Plasmablastic Lymphoma: Case Series From an Asian Tertiary Cancer Center and Literature Review. **2020**, 9, 71-78 1
- 350 Assessment of Viral RNA in Idiopathic Pulmonary Fibrosis Using RNA-seq.
- 349 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis. **2020**, 64, 219-225
- 348 Follicular lymphoma. **2020**, 22, 34-51 2
- 347 Hodgkin's lymphoma. **2020**, 22, 6-33 2
- 346 A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?. **2021**, 10, 2
- 345 Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. **2021**, 2
- 344 Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. *Journal of Clinical Oncology*, **2021**, JCO2101234 2.2 7
- 343 Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study. **2021**, 1-9

- 342 Treatment of Early Favorable Hodgkin Lymphoma. **2020**, 219-236
- 341 F-18 FDG PET Tests in Malignant Lymphoma. **2021**, 135-147
- 340 Prognostic Impact of Peripheral Blood T-Cell Subsets at the Time of Diagnosis on Survival in Patients with Diffuse Large B-Cell Lymphoma. **2021**, 144, 427-437 1
- 339 Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma. **2021**, 10, 1995166 1
- 338 Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis. **2021**, 30, 9636897211057077 2
- 337 Evolution of Clinical Trial Imaging and Co-clinical Imaging. **2020**, 239-253
- 336 A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive- and CD30-Positive Lymphomas.
- 335 [Chronic paraneoplastic inflammatory demyelinating polyradiculoneuritis secondary to nasal natural killer lymphoma]. **2020**, 36, 303
- 334 Radiologische Bildgebung: Differentielle Indikationsstellung ff.Diagnostik in der Onkologie (Röntgen, CT, MRT, Sonografie). **2020**, 1-19
- 333 Response Assessment and Follow-Up by Imaging in Gastrointestinal Tumours. **2020**, 475-494
- 332 PET in Lymphoma. **2020**, 685-729
- 331 PRIMARY BONE LYMPHOMAS: 18F-FDG PET AND PET-CT AS METHODS OF DIAGNOSIS AND EFFICACY ESTIMATION OF ANTITUMOR TREATMENT. **2020**, 13, 33-49
- 330 Therapy Response Imaging in Lymphoma and Hematologic Malignancies. **2020**, 177-200
- 329 Functional Imaging in Hodgkin Lymphoma. **2020**, 113-143
- 328 Metrics to Evaluate PET Response to Therapy Based on 3D Analysis. **2020**, 10, 133-142
- 327 Prognostic Factors. **2020**, 145-169
- 326 [Assessment of Viral RNA in Idiopathic Pulmonary Fibrosis Using RNA-seq.
- 325 Interim response in diffuse large B cell lymphoma on CT: what is the optimal size reduction (SPD) for predicting outcome?. **2020**, 30, 3094-3100

324	Clinical significance of oxidative stress for untreated patients with diffuse large B-cell lymphoma. 2022 , 16, 4	
323	Rituximab exposure-response in triweekly R-CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes. 2021 ,	2
322	Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. 2021 ,	
321	Current Role of Functional Imaging in the Management of Lymphoma. 2021 , 23, 144	1
320	Hematological Neoplasia. 2008 , 400-526	
319	A Case of Periaortic Lymphoma Mimicking Complicated Type B Acute Aortic Dissection: A Pitfall in the Endovascular Surgery Era. 2020 , 13, 312-315	
318	Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China. 2020 , 133, 2796-2802	0
317	Imaging techniques for Kaposi's sarcoma. 2008 , 13, 65-71	13
316	Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. 2007 , 1, 215-27	13
315	Semantic reasoning with image annotations for tumor assessment. 2009 , 2009, 359-63	7
314	The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma. 2010 , 2, 131-138	4
313	C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma. 2011 , 1, 204-14	1
312	Prognostic value of interim (18)F-FDG PET/CT in diffuse large B-cell lymphoma. 2013 , 25, 95-101	3
311	The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphoma. 2012 , 27, 141-4	2
310	PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with (18)F(-)labeled recombinant human His10-annexin V. 2015 , 5, 27-37	13
309	Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis. 2015 , 8, 15340-50	5
308	Small clonal B-cell population in the bone marrow as a possible tool in the diagnosis of occult primary parotid lymphoma. 2016 , 47, 59-62	4
307	Prognostic Value of FDG-PET, Based on the Revised Response Criteria, in Patients with Malignant Lymphoma: A Comparison with CT/MRI Evaluations, Based on the International Working Group/Cotswolds Meeting Criteria. 2015 , 3, 91-8	0

306	Mantle Cell Lymphoma: A North Indian Tertiary Care Centre Experience. 2016 , 17, 4583-4586	3
305	Diagnostic and Prognostic Relevance of Bone Marrow Microenvironment Components in Non Hodgkin's Lymphoma Cases Before and After Therapy. 2016 , 17, 5273-5280	2
304	Follicular lymphoma: an Institutional Analysis. 2017 , 18, 681-685	5
303	Consolidation radiotherapy for advanced-stage aggressive B-cell non-Hodgkin lymphoma: A systematic review and meta-analysis. 2017 , 16, 1233-1248	2
302	To Determine the Prognostic Significance of 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan-Derived Parameters (Total Lesion Glycolysis and Metabolic Tumor Volume) in Patients of Diffuse Large B-Cell Lymphoma with Only Nodal Involvement. 2020 , 35, 100-104	
301	[Efficacy of additional two cycles of rituximab administration for patients with diffuse large B-cell lymphoma in first remission]. 2016 , 37, 756-761	2
300	[Comprehensive geriatric assessment can predict the clinical outcomes of elderly patients with diffuse large B cell lymphoma in China]. 2018 , 39, 271-276	0
299	[High-dose methylprednisolone with Rituximab and fresh frozen plasma in the treatment of six patients with B-cell lymphoproliferative disorders harboring TP53 abnormalities]. 2019 , 40, 388-392	
298	[The prognostic significance of peripheral lymphocyte/monocyte ratio and PET-2 evaluation in adult Hodgkin's lymphoma]. 2019 , 40, 372-377	1
297	[Expression and prognostic value of CARD11 in diffuse large B cell lymphoma]. 2016 , 37, 30-4	2
296	[Clinical characteristics and outcome of 216 indolent B cell lymphomas]. 2016 , 37, 61-4	
295	[Expressions and clinical significance of GAS1, IL-1RAP and PRF1 in patients with ALK positive anaplastic large cell lymphoma]. 2018 , 39, 116-121	
294	[Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients]. 2015 , 36, 578-82	
293	[Interstitial pneumonia in patients with diffuse large B-cell lymphoma receiving RCHOP and RCDOP regimens]. 2019 , 40, 1015-1020	
292	[Clinical characteristics and survival analysis of eight cases HIV-negative plasmablastic lymphoma]. 2017 , 38, 290-294	2
291	[Long term efficacy of COPADM regimen in the treatment of 20 patients with Burkitt lymphoma]. 2018 , 39, 645-649	0
290	[Impact of solid tumor history on treatment response and survival of patients with diffuse large B-cell lymphoma]. 2019 , 40, 639-643	1
289	[Efficacy of RCDOP regimen in the treatment of patients with diffuse large B-cell lymphoma]. 2018 , 39, 485-490	0

- 288 [Efficacy and prognostic analysis of 98 cases of relapsed/refractory diffuse large B-cell lymphoma treated with second-line regimens]. **2017**, 38, 511-516 1
- 287 [Non-upper aerodigestive tract NK/T- cell lymphoma: an analysis of clinical features and survival from a single center in China]. **2015**, 36, 29-33 1
- 286 [Clinical characteristics and prognostic analysis of 90 patients with primary gastro-intestinal marginal zone lymphoma]. **2015**, 36, 24-8
- 285 [Clinical analysis of 25 patients with aggressive peripheral T-cell lymphoma in advanced stage treated with autologous stem cell transplantation]. **2015**, 36, 455-9 1
- 284 [Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma]. **2016**, 37, 269-72
- 283 [The prognostic value of lower pretreatment advanced lung cancer inflammation index (ALI) in B cell lymphoma]. **2018**, 39, 53-55
- 282 [Efficacy and prognostic analysis of relapsed/refractory diffuse large B-cell lymphoma patients with hepatitis B virus infection]. **2018**, 39, 1017-1020 2
- 281 [Comparisons of efficacy and safety of CBV, BEAM and BEAC high-dose therapy followed by autologous hematopoietic stem cell transplantation in Hodgkin's lymphoma]. **2017**, 38, 716-719 1
- 280 [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy]. **2017**, 38, 772-777 1
- 279 [Outcome of haploidentical hematopoietic stem cell transplantation for non-Hodgkin lymphoma]. **2016**, 37, 656-60 1
- 278 [Prognostic study of 229 follicular lymphoma patients treated with rituximab combined with chemotherapy]. **2019**, 40, 46-51
- 277 [A clinical analysis of 10 cases with cardiac lymphoma]. **2017**, 38, 102-106 1
- 276 [Autologous hematopoietic stem cell transplantation treatment for T cell lymphoblastic lymphoma]. **2020**, 41, 198-203
- 275 [A multicenter investigation and analysis on anemia in lymphoma patients in Shanghai]. **2020**, 41, 123-127
- 274 [Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma]. **2020**, 41, 462-468 1
- 273 [Relationship between p53 rs1625895 polymorphism and prognosis in diffuse large B-cell lymphoma]. **2019**, 51, 791-796
- 272 Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma. **2020**, 10, 97-108 3
- 271 Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type. **2020**, 10, 4498-4512 5

270	[IEAC versus CEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for lymphoma: analysis of efficacy and safety in 106 cases]. 2020 , 40, 1760-1767	
269	Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma. 2021 , 5, 1412-1424	0
268	[The prognostic impact of diabetic mellitus and hyperglycemia during DLBCL treatment on patients with diffuse large B-cell lymphoma]. 2021 , 42, 151-157	
267	Deep learning convolutional neural network (DLCNN): unleashing the potential of F-FDG PET/CT in lymphoma. 2021 , 11, 327-331	0
266	Computer-aided detection of mantle cell lymphoma on F-FDG PET/CT using a deep learning convolutional neural network. 2021 , 11, 260-270	1
265	Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival. 2021 , 20, 15330338211056478	0
264	Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions). 2022 , 17, 145-174	3
263	Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis. 2021 , 21, 1255	0
262	Surgery and Chemotherapy versus Chemotherapy Only in Older Persons with Primary Intestinal Diffuse Large B-Cell Lymphoma. 2021 , 13, 8831-8839	1
261	CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. 2021 , 1-5	1
260	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. 2021 ,	1
259	Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in patients with primary T cell lymphomas. 2021 ,	
258	Assessment of Early Therapy Response of Non-Hodgkin's and Hodgkin's Lymphoma Using B-Mode Ultrasound and Dynamic Contrast-Enhanced Ultrasound. 2021 ,	0
257	The Use of PET in Evaluating the Efficacy of Immunotherapy in Oncology. 2022 , 471-493	
256	Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma. 2021 ,	0
255	Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. 2021 , 1-8	0
254	Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. 2021 ,	1
253	Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Source and Disease Characteristics. 2021 ,	0

252	The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.. 2022 , 12, 36	0
251	Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma.. 2021 , 11, 797028	0
250	Clinicopathological characteristics and treatment outcomes of cutaneous extranodal natural killer/T-cell lymphoma: a retrospective study in China.. 2020 , 9, 6096-6106	
249	Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL).. 2022 , 101, 789	
248	PET imaging of hematological neoplasia. 2022 ,	
247	A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.. 2022 , 1-12	0
246	Matching design for augmenting the control arm of a randomized controlled trial using real-world data.. 2022 , 1-17	1
245	Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study.. 2022 , 14,	1
244	Radiomics Features of the Spleen as Surrogates for CT-Based Lymphoma Diagnosis and Subtype Differentiation.. 2022 , 14,	1
243	Exploring the Interobserver Agreement in Computer-Aided Radiologic Tumor Measurement and Evaluation of Tumor Response.. 2021 , 11, 691638	
242	Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome.. 2022 , 13, 788824	
241	OUP accepted manuscript.	0
240	Indirect Comparison of Tisagenlecleucel and Historical Treatments for Relapsed/Refractory Diffuse Large B-cell Lymphoma.. 2022 ,	0
239	Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of 2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China.. 2022 , 2022, 1080879	
238	Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. 2022 , 3, 139-153	1
237	Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of Mantle Cell Lymphoma and a Large Pan-Cancer Series.. 2022 , 10,	3
236	Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review.. 2021 , 11, 796270	0
235	Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101777	2.2 1

234	Longitudinal CT Imaging to Explore the Predictive Power of 3D Radiomic Tumour Heterogeneity in Precise Imaging of Mantle Cell Lymphoma (MCL).. 2022 , 14,	2
233	Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination.. 2022 , 12, 796738	0
232	Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.. 2022 ,	0
231	Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma.. 2022 , 6, e675	
230	Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors.. 2022 , 12, 1753	1
229	Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy.. 2022 ,	1
228	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100931	15
227	Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India.. 2021 , 11, 799948	
226	The outcome of watchful waiting in patients with previously treated follicular lymphoma.. 2022 ,	
225	Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.. 2021 , 65, 402-409	
224	A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogeneic PBSCT.. 2022 , 1	
223	Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: a single-center, retrospective, cohort study.. 2022 ,	0
222	Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after 3 or more lines of prior therapy: evidence of durable benefit.. 2022 ,	1
221	The ECHELON-2 Trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.. 2021 ,	3
220	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. 2021 ,	45
219	Clinical Features and Prognostic Significance of Mutations in Diffuse Large B-Cell Lymphoma.. 2021 , 11, 746577	1
218	Prognostic Role of the Expression of Latent-Membrane Protein 1 of Epstein-Barr Virus in Classical Hodgkin Lymphoma.. 2021 , 13,	1
217	Thoracic Imaging Manifestations of Treated Lymphomas: Response Evaluation, Posttherapeutic Sequelae, and Complications.. 2022 , 37, 67-79	

216	Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial.. 2022 , 6, e699	1
215	Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.	0
214	Dual-Layer Spectral Detector CT in Comparison with FDG-PET/CT for the Assessment of Lymphoma Activity.. 2022 ,	
213	A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma.. 2022 , 11, 9	
212	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.. 2021 ,	0
211	Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.. 2022 , 1-9	2
210	A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib. 2022 , 39, 1678	0
209	Oratumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma, results of a phase 2 study.. 2022	
208	Interpretation of 2-[F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors.. 2022 , 1	1
207	Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma.. 2022 ,	
206	HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal, South Africa.. 2022 ,	
205	CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.. 2022 , 13, 829366	
204	Relapse in patients with limited-stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended follow-up of a phase 2 study.. 2022 ,	0
203	Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group.. 2022 , 14,	
202	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.. 2022 , 6, 13	1
201	Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma.. 2022 , 101, 979	1
200	Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells.. 2022 , 7, 80	1
199	Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.. 2022 ,	0

198	Possibility of PET/CT in Patients with Extranodal Diffuse Large B-Cell Lymphoma of Stomach at Different Treatment Stages. 2022 , 5, 37-45	
197	Odronektamab, a human CD20/CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.. 2022 ,	9
196	Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.. 2022 ,	
195	A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.. 2022 ,	0
194	Finding a consensus on time-to-event endpoints definitions in Marginal Zone Lymphoma: a Delphi method.. 2022 ,	
193	A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.. 2022 ,	0
192	Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma.. 2021 , 58,	0
191	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. 2021 , 1-13	0
190	Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment.. 2021 , 14,	2
189	Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study.. 2021 , 9, 1769	1
188	Treatment of adult Burkitt lymphoma with the CALGB 1002 protocol: a single center experience in Jordan. 2021 ,	0
187	Follicular lymphoma treated with first-line immunochemotherapy: a review of PET-CT in patients who did not achieve CMR in the GALLIUM study. 2021 ,	0
186	Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.. 2021 , 1-12	1
185	90Y-ibritumomab tiuxetan in B-cell non-Hodgkin lymphomas: Real-world data from the United Arab Emirates. 2021 , 100882	
184	Kikuchi Disease Masquerading as a T-Cell Lymphoma. 2022 , 27, 80-83	
183	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.. 2022 , 15, 36	2
182	Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.. 2022 , 22, 403	0
181	Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: a systematic review of literature.. 2022 ,	0

- 180 Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma.. **2022**, 27, 404-411 ○
- 179 International staging and response criteria for lymphomas. 277-285
- 178 Treatment approach to diffuse large B-cell lymphomas. 286-307
- 177 Hodgkin lymphoma: epidemiology, diagnosis, and treatment. 367-403
- 176 image_1.tif. **2018**,
- 175 image_2.tif. **2018**,
- 174 DataSheet_1.pdf. **2020**,
- 173 DataSheet_2.pdf. **2020**,
- 172 Table_1.xlsx. **2019**,
- 171 Table_2.xlsx. **2019**,
- 170 Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.. **2022**, 1-9
- 169 Role of Stem Cell Transplant in CD30-positive PTCL following Frontline Brentuximab Vedotin+CHP or CHOP in ECHELON-2.. **2022**, ○
- 168 A Phase I trial of talazoparib in patients with advanced hematologic malignancies. **2021**, 10, IJH35
- 167 [MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].. **2022**, 43, 41-47
- 166 [Dose-enhanced immunochemotherapy followed by first-line autologous peripheral blood stem cell transplantation for young patients with high-risk aggressive B-cell lymphoma: an efficacy and prognostic factor analysis].. **2022**, 43, 215-220
- 165 The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a novel prognostic factor for patients with diffuse large B-cell lymphoma. **2022**, ○
- 164 Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT.. **2022**, 57, 75-78 ○
- 163 FDG PET/CT and Dosimetric Studies of Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?. **2022**, ○

- 162 Utility and limitations of metabolic parameters in head and neck cancer: finding a practical segmentation method.. **2022**, 1
- 161 Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.. **2022**, 2
- 160 Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.. **2022**,
- 159 Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study. **2022**, 12,
- 158 Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma.. **2022**, 13, 888250 0
- 157 End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.. **2022**, 0
- 156 The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis.. **2022**, 1
- 155 Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era.. **2022**, 1
- 154 Long-Term Outcomes and Safety Trends of Autologous Stem-Cell Transplantation in Non-Hodgkin Lymphoma: A Report From A Tertiary Care Center in India.. **2022**, 8, e2100383
- 153 Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma. **2022**, 2, 307-315 1
- 152 gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.. **2022**, 2
- 151 PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.. **2022**, 12, 78 0
- 150 Monitoring Gastrointestinal Tumor Response to Therapy. **2015**, 2295-2305
- 149 Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.. **2022**,
- 148 Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments.. **2022**, 103711
- 147 The role of surveillance computed tomography in patients with follicular lymphoma.. **2022**, 13, 20406207221095963
- 146 Diagnostic Applications of Nuclear Medicine: Lymphomas. **2022**, 1-45
- 145 Enhancement of the International prognostic index with β_2 -microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era. **2022**, 22, 0

144	Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients. 2022 , 14, 2532	
143	Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma. 2022 , 13,	0
142	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. 2022 , 14, 2673	0
141	Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial.	
140	Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B Cell Lymphoma. 2022 ,	0
139	Real-world Evidence of Axicabtagene Ciloleucel for the Treatment of Large B-Cell Lymphoma in the United States. 2022 ,	1
138	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.	3
137	Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma.	0
136	Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters. 12,	0
135	High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up. 2022 , 12,	
134	Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. 2022 , 10, e004984	2
133	Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study. 1-7	
132	Factors Associated with Discontinuation of Statin Therapy in Patients with Lymphoma Aged 80 Years and Older: A Retrospective Single-Institute Study.	
131	Clinicopathologic Characteristics Associated with Prognosis in Ocular Extranodal Marginal Zone B Cell Lymphoma. 2022 , 58, 818	
130	18F-FDG PET maximum intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients. jnumed.121.263501	0
129	Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. 1-14	0
128	Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis. 2022 , 27, 757-764	
127	Synchronous multiple primary tumors in patients with malignant lymphoma: a retrospective study. 2022 , 22,	

126	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. OF1-OF15		0
125	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. <i>Journal of Clinical Oncology</i> ,	2.2	1
124	The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients.		0
123	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.		3
122	Statistical handling of death events in the analysis of time to progression: A review of oncology journals. 2022 , 106858		
121	Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma.		
120	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. 2022 ,		5
119	Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma.		0
118	Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.		
117	A Phase 1 Study of Pelabresib (CPI-0610), a Small Molecule Inhibitor of BET Proteins, in Patients With Relapsed or Refractory Lymphoma.		0
116	Pirarubicin-based intensive chemotherapy followed by consolidative high-dose chemotherapies for peripheral T-cell lymphomas: A noncomparative phase 2 study.		
115	Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. OF1-OF11		1
114	Impact of relative dose intensity of R-CCOP regimen in elderly patients with diffuse large B-cell lymphoma in China. 2022 ,		0
113	A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan.		
112	APPLICATION OF THE LUGANO CLASSIFICATION FOR INITIAL EVALUATION, STAGING, AND RESPONSE ASSESSMENT OF HODGKIN AND NON-HODGKIN LYMPHOMA: THE PROLOG CONSENSUS INITIATIVE (PART 2- TECHNICAL). <i>jnumed.122.264124</i>		1
111	APPLICATION OF THE LUGANO CLASSIFICATION FOR INITIAL EVALUATION, STAGING, AND RESPONSE ASSESSMENT OF HODGKIN AND NON-HODGKIN LYMPHOMA: THE PROLOG CONSENSUS INITIATIVE (PART 1- CLINICAL). <i>jnumed.122.264106</i>		1
110	Assessing Response to Therapy. 2023 , 28-38		
109	Hematologic Malignancy: The Lymphomas. 2023 , 529-554		

- 108 Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study.
- 107 Long-term survival outcomes of patients with primary ocular adnexal MALT lymphoma: A large single-center cohort study.
- 106 Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors. 0
- 105 Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. 1
- 104 Clinical characteristics and treatment of NK/T-cell lymphoma-associated HLH. 0
- 103 Dual epigenetic agents plus rituximab-gemcitabine-xalipatin as salvage treatment in relapsed/refractory diffuse large B-cell lymphoma patients failure of salvage chemotherapy.
- 102 Multimodal deep learning model on interim [18F]FDG PET/CT for predicting primary treatment failure in diffuse large B-cell lymphoma. 0
- 101 Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients. 13, 1
- 100 Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma.
- 99 Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma. 0
- 98 Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design. 1-8
- 97 Patient characteristics and outcome of CD20-positive HIV-associated lymphoma: a single-center KwaZulu-Natal, South African hospital 12-year retrospective review. 2022, 34, 0
- 96 Long-term treatment outcome of Castleman's disease: A real-world experience. 12,
- 95 Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study. 0
- 94 Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. 0
- 93 Multidimensional modeling of solid tumor proliferation following drug treatment: Toward computational prognosis as a tool to support oncology. 2022, 435-454 0
- 92 Diagnostic Applications of Nuclear Medicine: Lymphomas. 2022, 431-474 0
- 91 A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma. 0

90	Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy. 13,	1
89	CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China. 2022 , 50, 030006052211100	0
88	Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.	0
87	Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival. 2022 , 6, e781	0
86	Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder. 13,	0
85	Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China.	0
84	Improving outcomes for high-risk DLBCL: a pilot study looking at the role of fractionated cyclophosphamide with RCHOP chemo-immunotherapy (SCUBA-1 trial).	0
83	DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis. 2022 , 101, e30620	0
82	CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.	0
81	Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous TransplantationâPhase I Study. 2022 , 11, 5378	0
80	Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.	3
79	The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy. 2022 , 17, e0273839	0
78	Ocular adnexal lymphoma: Subtype-specific clinical and genetic features. 2022 , 100, 3-37	0
77	Genetic and phenotypic characterisation of HIV -associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.	0
76	Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series.	0
75	Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma. 13,	0
74	Biomedical impact of the expression of HOX locus-associated LncRNAs HOTAIR and HOTTIP in diffuse large B cell lymphoma. 2022 , 34, 201112	0
73	The Role of 18FDG-PET/CT in Malignant Lymphomas Clinical Implications. 2022 , 109-151	0

72	Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.	○
71	Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response.	○
70	Impact of Implementing a Bendamustine-based Conditioning Regimen on outcomes of Autologous Stem Cell Transplant in Lymphoma while Novel Cellular Therapies Emerge. 2022 ,	○
69	Positron Emission Tomography-adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).	○
68	Safety and Feasibility of Anti-CD19 CAR T Cells Expressing Inducible IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-cell Lymphoma.	○
67	Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study.	○
66	Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD. 12 ,	○
65	Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study. 1-7	○
64	Association between genetic variants and the risk of nivolumab-induced immune-related adverse events.	○
63	Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018). 2022 ,	○
62	Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma. 2022 ,	○
61	Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels. 2022 , 14 , 5318	1
60	Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T Cell Therapy in Adults with high-risk Relapsed/Refractory ALL.	1
59	Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS) -associated lymphomas.	○
58	Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. 2022 , 12 ,	○
57	A systematic review of contemporary phase I trials in patients with lymphoma. 2022 , 180 , 103860	○
56	Identification of prognostic factors in classic Hodgkin lymphoma by integrating whole slide imaging and next generation sequencing.	○
55	Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in Europe.	○

54	Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy. 1-11	0
53	Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics via Phenotypic Differentiation. 2022 , 14, 5576	0
52	Immunophenotypic transformation in relapsed/refractory mantle cell lymphoma treated with human anti-CD5 chimeric antigen receptor T cells: A Case Report. 1,	0
51	Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System. 2022 ,	0
50	PET/CT in Hodgkin Lymphoma: An Update. 2022 ,	1
49	Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.	0
48	Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy. 2022 , 6, e798	0
47	T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy. 2022 , 12,	1
46	First-line antibiotic treatment in patients with localized extragastric mucosa-associated lymphoid tissue lymphoma.	0
45	Rituximab PK and PKPD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarity.	0
44	Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas. 2022 , 13, 1237-1244	0
43	Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. 2022 ,	0
42	Randomized, Placebo-Controlled, Phase 3 Trial of PI3K Inhibitor Leniolisib for Activated PI3K Syndrome.	2
41	A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.	0
40	Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma. 2023 , 12,	0
39	Bridging to Transplant in Diffuse Large B Cell Lymphoma. 91-99	0
38	CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.	1
37	Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. 13,	0

- 36 Influence of the methodological aspects of the dichotomization of total metabolic tumor volume measured through baseline fluorine-18 fluorodeoxyglucose PET on survival prediction in lymphoma. **2023**, 44, 74-80 ○
- 35 Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. **2022**, 11, 7162 1
- 34 Predictive value on advance Hodgkin Lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial. ○
- 33 High-intensity chemotherapy improved the prognosis of patients with high-grade B-cell lymphoma. 13, ○
- 32 Outcomes of older adults with non-Hodgkin lymphoma undergoing autologous stem cell transplantation: a Mayo Clinic Cohort Analysis. **2022**, ○
- 31 Efficacy and Safety of PD - 1 Inhibitor alone or Combined with Chemotherapy in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma: A Retrospective Study. ○
- 30 Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas. ○
- 29 IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma. ○
- 28 Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies. **2023**, 24, ○
- 27 Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor. **2023**, 12, 618 ○
- 26 Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. ○
- 25 Radiologic assessment of tumor response to immunotherapy and its complications. **2023**, 239-261 ○
- 24 Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). **2023**, 14, 57-70 ○
- 23 Novel CD19-specific α /TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma. **2023**, 16, ○
- 22 Clinical outcomes in patients relapsed/refractory after ≥ 2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis. **2023**, 23, ○
- 21 Perspectives on the Treatment of Mantle Cell Lymphoma and Follicular Lymphoma in 2015 and Beyond. 54-64 ○
- 20 FDG PET/CT-based Response Assessment in Malignancies. **2023**, 43, ○
- 19 Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. ○

- 18 Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution. **2023**, 136, 167-175 ○
- 17 Prediction of miRNA-disease associations by neural network-based deep matrix factorization. **2023**, 212, 1-9 ○
- 16 Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study. **2023**, 24, 252-261 ○
- 15 Myeloid and Lymphoid Disorders in Geriatric Patients. **2023**, 427-444 ○
- 14 Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance. ○
- 13 Multisystem Imaging Recommendations/Guidelines: In the Pursuit of Precision Oncology. **2023**, 44, 002-025 ○
- 12 Prognostic value of PET / CT and CT in T-cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients. **2023**, 201, ○
- 11 Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study. **2023**, ○
- 10 Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. ○
- 9 Use of obinutuzumab in therapy of patients with newly diagnosed follicular lymphoma. Experience of the Oncohematology Division of the Clinical Hospital "Apino" **2023**, 3, 53-60 ○
- 8 Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem). ○
- 7 Application of the Central Nervous System International Prognostic Index (CNS-IPI) score in daily practice: a retrospective analysis apart from the clinical trial at two centers in Brazil. **2023**, ○
- 6 Four-dimensional quantitative analysis using FDG-PET in clinical oncology. ○
- 5 Biology-Guided Radiation Therapy. **2023**, ○
- 4 Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis. **2023**, 7, e860 ○
- 3 Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. **2023**, 7, e837 ○
- 2 Report of Consensus Panel 4 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on Diagnostic and Response Criteria. **2023**, ○
- 1 Long term results with thiotepa containing regimen (TECAM) for autologous stem cell transplantation. **2023**, ○

